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CHAPTER ONE 
INTRODUCTION TO TISSUE ENGINEERED BLOOD VESSELS 
Introduction to Tissue Engineering 
  “Tissue engineering,” as originally described by Robert Langer and Joseph 
Vacanti, is "an interdisciplinary field that applies the principles of engineering and life 
sciences toward the development of biological substitutes that restore, maintain, or 
improve tissue function.”9 In practice, the potential applications for tissue engineering are 
as broad and inclusive as the methods and modalities employed to achieve the above 
described goal. The somewhat amorphous field includes endeavors which range from the 
decellularization of existing tissues for implantation in the body, as in many 
commercially available abdominal wall hernia meshes and biologic heart valves, to the 
yet unrealized goal of organ creation de novo for complex applications such as organ 
transplantation.  
 The intrinsic multidisciplinary nature of tissue engineering, while allowing for 
exciting, unusual, and often “out of the box” project development, nevertheless dictates 
that optimal results will be achieved at the delicate intersection of stringent hypothesis-
based research and the almost alchemic creativity of bioengineering. The following 
project attempts to approach this intersection by describing a strategy for the 
development of a microvascular network in a commonly used tissue engineering scaffold, 
while investigating the basic biologic processes which affect their creation. The
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microvascularization of tissue engineered organs, including tissue engineered blood 
vessels large enough for use as vascular conduits for bypass or for organ perfusion, is 
thought to be a critical need in tissue engineering. The ultimate goal of this project, 
hopefully, is to both elucidate the basic mechanisms in the angiogenic process which can 
be exploited and altered for the practical purpose of tissue construction, in the case of this 
project a tissue engineered blood vessel (TEBV), and demonstrate a modality for the 
creation of more complex and precise 3-D in vitro models which may be used to model in 
vivo biologic processes in the laboratory. 
Introduction to Tissue Engineered Blood Vessels 
The Clinical Need for Biologic Alternatives to Synthetic Vascular Bypass Grafts 
 Since its first use in 1906 by Goyanes to repair a popliteal arterial aneurysm,10 
native autogenous vessels have served as the gold standard material in the treatment of 
many vascular diseases. They function as bypass conduits for aneurysmal defects and 
stenoses in the peripheral or coronary vascular system, as patches for the closure of 
arteriotomies, or as conduits for the creation of arteriovenous fistulae for patients 
receiving hemodialysis. However, a significant percentage of patients lack suitable 
autogenous vessels for use in vascular interventions either due to intrinsic vascular 
disease or due to their use in previous vascular procedures. For these patients, alternative 
synthetic grafts comprised most commonly of expanded polytetrafluoroethylene (ePTFE) 
and polyethylene terephthalate (PET) are the most commonly used when suitable 
autogenous vessels are lacking.  
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 While these synthetic alternatives have generally been suitable for the bypass of 
larger vessels, their long-term success in bypasses of arteries of smaller caliber (<6 mm) 
has been limited. The inferiority of ePTFE in comparison to native vessel conduits such 
as saphenous vein is most pronounced for the bypass of more distal targets. In addition, 
while bypass of the femoral artery to the more proximal target of the popliteal artery 
above the knee with ePTFE has demonstrated comparable rates of patency in comparison 
to saphenous vein within the first year or two, it is apparent that the intermediate to 
longer term results of these more proximal bypasses are also less successful. The primary 
5 year patency (the duration of follow-up in which there is an absence of occlusion or 
clinically significant restenosis within the treated segment) of bypasses from the femoral 
artery to the popliteal artery above the knee utilizing saphenous vein range from 73%- 
77.2% versus 39%-57% for bypasses utilizing ePTFE.11,12 The patency of bypasses to the 
popliteal artery below the knee are significantly worse than the patency of bypasses to the 
above-knee popliteal artery. Long term results of infrapopliteal bypasses (bypasses to the 
tibial or peroneal arteries) with ePTFE are even less successful. In a meta-analysis of 43 
studies, pooled estimates for the 5 year primary patency, secondary patency (patency that 
has been restored by the treating physician after occlusion of the treated arterial segment), 
and limb salvage rates of infrapopliteal bypasses with ePTFE were 30.5%, 39.7%, and 
55.7%, respectively.13 Although not commonly used for infrainguinal bypasses, PET 
(tradename Dacron) demonstrates comparable patency rates to ePTFE when used for 
femoro-femoral, axillo-femoral, or femoro-popliteal bypasses.14-16 
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 These poor intermediate and long-term results of available synthetic conduits used 
for bypasses in the peripheral vasculature in comparison to those of native vessels have 
led researchers to investigate the creation of wholly tissue engineered biologic alternative 
for patients lacking suitable autogenous vessels.  Among the strategies detailed below for 
creating these biologic alternatives include constructing conduits comprised of hydrogels 
such as fibrin, collagen, polyethylene glycol (PEG), and others.  It is our overall 
hypothesis that biologic alternatives with sufficient thickness to withstand the pulsatile 
pressures of the circulatory system will require a vasa vasorum to support smooth muscle 
cells within the outer 2/3’s of the blood vessel tunica media.  The studies described in the 
Aims of this study are meant to model both the technical creation of these hydrogel based 
blood vessel alternatives as well as the basic biologic processes which occur during the 
angiogenic development of the vasa vasorum within the wall of these constructs. 
Strategies for Engineering Blood Vessels 
 The studies within this project are meant to model angiogenic processes within 
the tissue engineered blood vessel tunica media. For clarification purposes, the term 
“tissue engineered blood vessel (TEBV)” refers to the muscular arteries utilized as 
conduit alternatives, while the term “engineered microvasculature” refers to the 
engineered capillaries which will serve as the source of the TEBV vasa vasorum. The 
following is a brief introduction to major strategies for the creation of tissue engineered 
blood vessels in order to provide context to the studies within this dissertation.   
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General Concepts 
 While methodologies described in the literature for the development of a TEBV 
can seem infinitely variable, they are founded on one ultimate goal.  That is to organize a 
structure comprised of cells and extracellular matrix (ECM) which mimics the biologic 
functionalities of a native blood vessel, including mechanotransduction and 
vasoreactivity for the maintenance of vessel wall and hemodynamic homeostasis.  
Specifically, a TEBV should be comprised of a cellular intimal component containing a 
quiescent, anti-thrombogenic endothelial monolayer that transduces signals from shear 
and cyclic stresses created by blood flow and a TEBV media comprised of organized 
quiescent and vasoactive smooth muscle cells (SMCs).  The extracellular matrix 
component should be organized circumferentially by an internal and external elastic 
lamina, and an arterial media organized as fibers of collagen and elastin oriented 
perpendicular to the direction of blood flow to allow for proper compliance and elastic 
mechanical compatibility.  Additionally, a vasa vasorum which anastomoses with the 
host vasculature, hypothetically required for the long-term viability of cells within the 
outer 1/3 to 2/3 of the arterial media and adventitia incapable of receiving nutritional and 
oxygen support from the circulating blood flow (discussed in the following chapter).  The 
engineering of an adventitia which provides mechanical support as well as vascular 
support for the TEBV is a less common focus, but is likely to be of some importance in 
the construction of a TEBV (Figure 1). 
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Figure 1.  Components of the vessel wall.4 
Investigating optimal methodologies and materials for organ cellularization, the 
construction or direction of ECM deposition, and the allowance for proper cell-matrix 
interactions requisite to the aforementioned biologic functionalities are theoretically 
endless and among the widely studied topics.   The broad strategic categories in tissue 
engineering include 1) the implantation of cells, materials, and bioactive molecules and 
drugs in vivo, utilizing the host body as a living bioreactor which responds to the 
implanted agents and formulates the final structure after implantation; 2) the complete 
creation of a tissue or organ ex vivo prior to implantation; or 3) a combination of both 
strategies.   
 The sourcing of the cellular component, the materials utilized as scaffolds or drug 
delivery vehicles, and the nature of the genetic and protein level manipulations are 
fundamental and exciting territories in the field of tissue engineering.  In addition, due to 
the advent of bioresorbable materials, the engineering of blood vessels from 
bioresorbable polymers which are replaced by the host tissue as a result of normal 
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vascular healing has become a possibility.  The following discussion will focus on 
hydrogel-based TEBVs, a widely supported approach for TEBV construction, and the 
strategy which the studies of this project are intended to model.  It will also briefly 
describe the concept of self-assembled TEBVs, bioresorbable TEBVs, and TEBVs 
constructed from decellularized vessels. 
Hydrogel-Based TEBVs 
 Natural hydrogel polymers such as fibrin, collagen, alginate, hyaluronan, as well 
as synthetic hydrogels such as poly-ethylene glycol (PEG) and polyvinyl alcohol are 
commonly used in tissue engineering as scaffolds or components of scaffolds for a 
variety of engineered tissues including TEBVs, and are the strategy which is modeled 
within this dissertation.17 The first credited attempt at the creation of a TEBV by 
Weinberg and Bell in 1986 utilized a collagen hydrogel scaffold constructed as a tubular 
structure with concentric layers of endothelial cells, smooth muscle cells and 
fibroblasts.18  While poor burst strengths, a common limitation to hydrogel based TEBVs, 
necessitated the use of supporting sleeves, comprised of PET in the Weinberg and Bell 
studies, for mechanical support, these investigators demonstrated the feasibility of TEBV 
creation utilizing hydrogels as scaffolds.  In addition, while early and most current 
studies focus on early mechanical properties ex vivo, a full understanding of the short and 
long-term mechanical and cell functional properties will require in vivo studies in animal 
models.   
 Several modifications to hydrogel based TEBVs have been developed in order to 
improve the mechanical strength of the constructs.  These include chemical modifications 
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which regulate the degradation of the hydrogel matrix, induce the cellular deposition of 
endogenously produced matrix proteins like collagens and elastins, and promote covalent 
cross linking among ECM fibers.  For example, mechanical properties of fibrin-based 
TEBVs can be modified by the addition of plasmin inhibitors such as aprotinin, cross-
linking agents, and media supplements such as insulin and TGF-β which induce 
endogenous matrix deposition by embedded cells.19,20  The use of media supplements 
such as retinoic acid and ascorbic acid has been shown to promote SMC elastin and 
collagen mRNA and protein expression within type I collagen tubular constructs.21  This 
was associated with increased TEBV tensile strength and decreased stiffness compared to 
untreated TEBVs.   Finally, TEBVs can be constructed in layers varied by the 
composition of the ECM and cellular component, with each layer performing separate 
functions.  For example, fibrin-based TEBVs with an inner layer containing a lower 
concentration of fibrinogen to support SMC vasoactivity, and an outer cell-free layer 
comprised of a higher concentration of fibrinogen for mechanical stability demonstrated 
significantly improved burst strengths compared to single layer constructs while 
maintaining vasoreactivity.22   
 Mechanical preconditioning with cyclic strain bioreactors has also been 
efficacious in improving the structural integrity of hydrogel based TEBVs.  In collagen 
based constructs, this has been shown to be attributable in part by the modulation of cell 
and matrix organization, as well as by the alteration of the expression of matrix 
metalloproteases (MMPs).23,24  Recent studies also demonstrated that the application of 
incremental cyclic distention from 5% to 15% significantly improved tensile strength, 
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tensile modulus, and collagen deposition per cell in fibrin-based TEBVs.25  In addition, a 
direct comparison of the mechanics of fibrin, collagen, and fibrin-collagen TEBVs 
showed that the mechanical properties of the TEBV were not only dependent on the 
application of mechanical strain, but also on the composition of the hydrogel scaffold.26  
Linear modulus was directly associated with collagen content, and gel compaction (a 
process resulting in a more compact matrix secondary to cellular behavior or 
biomechanical stimuli), which was associated with improved tensile strength, was 
augmented by the addition of fibrin.  This study also found that cyclic mechanical strain 
not only augmented the tensile strength and gel compaction of collagen-fibrin TEBVs, 
but also decreased cellular proliferation.  The effects of mechanical strain on cellular 
phenotype is further exemplified by increased levels of vWF, nitric oxide, SMC α-actin, 
and SMC myosin heavy chain in mechanically conditioned collagen/PLGA (poly (lactic-
co-glycolic acid)) TEBVs containing ECs and SMCs compared with statically cultured 
TEBVs.27  In addition, this study demonstrated that mechanical strain affected cellular 
orientation, with embedded cells aligning radially in mechanically conditioned TEBVs in 
contrast to the random alignment of statically cultured TEBVs.      
Bioresorbable TEBVs 
 Bioresorbable materials can serve as temporary scaffolds for vascular prostheses 
which are replaced by the native tissue or as polymeric vehicles from which drugs can be 
eluted with controlled kinetics.  Implanted devices comprised of these materials, such as 
drug eluting stents, can serve their functional purpose for the time it is required and then 
histologically “disappear,” theoretically minimizing the long-term inflammatory and 
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injury responses and the potential for graft infection.   As a scaffold for a tissue 
engineered blood vessel, bioresorbable materials can serve as “smart” materials that are 
modified to promote native tissue infiltration after implantation.  Knowledge of the 
resorption kinetics of specific bioresorbable materials based on the intrinsic properties of 
the materials being used are critical to controlling host-material interactions which lead to 
tissue incorporation.28-31   
 Some clinical experiences with bioresorbable grafts have provided encouraging 
results.  Because current synthetic prosthetic materials cannot grow proportional to the 
growth of the native tissue during child development, bioresorbable TEBVs are 
especially useful in the pediatric population.  TEBVs comprised of a composite PGA 
((polyglycolic acid )/poly-4-hydroxybutyrate (P4HB)) scaffold were seeded with vascular 
cells and implanted in the pulmonary arteries of a growing lamb model in which body 
size doubled over a two year period.32  Similar to the growth of native vessels, the 
TEBVs demonstrated a 30% increase in diameter and a 45% increase in length over time, 
with concomitant increases in collagen, proteoglycan, and cellular content.  In addition, 
there was no evidence of thrombus formation, calcification, stenosis, suture dehiscence, 
or aneurysm in any of the implanted grafts.  Decreased elasticity and an absence of 
elastin in the TEBVs in comparison to native pulmonary arteries was noted, however.   
 In 2001, a TEBV comprised of a bioresorbable polycaprolactone (PCL) / 
polylactic acid (PLA) tubular scaffold seeded with autogenous cells were implanted into 
the pulmonary artery of a 4 year old child with pulmonary artery atresia.33  At seven 
month follow up, the patient was doing well, with no evidence of aneurysm formation or 
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graft occlusion.  Subsequent efforts utilized autologous bone marrow cells as a cell 
source to seed hybrid scaffolds of a copolymer of PLA and PCLA with a PGA 
reinforcement. These were implanted as grafts for extracardiac total cavopulmonary 
connections in 23 patients (ages 1-24) with congenital heart defects with a 6 year follow-
up.33,34  Computed tomography studies did not demonstrate evidence of aneurysmal 
dilation and there was only one case of graft stenosis which was successfully treated with 
angioplasty.  With evidence of growth of the vessel conduit over the time period, these 
results provided encouraging initial clinical experiences.  The investigators have received 
IRB approval and are hoping to begin clinical trials in the United States in the near 
future. 
Self-Assembled TEBVs 
 A promising strategy for TEBV construction which has been tested in human 
subjects is the self-assembly strategy described by L’Heureux and Auger et. al.35  Human 
SMCs were cultured with ascorbic acid and served as a cellular sheet which was wrapped 
around a tubular support to produce the media of the vessel. A second sheet generated by 
cultured human fibroblasts was then wrapped around the media to provide the vessel 
adventitia.  After a period of culture, the tubular support was removed and ECs were 
seeded onto the lumen of the TEBVs.  This methodology is advantageous as it avoids the 
use of any foreign materials, and relies on the cellular components to provide for the 
ECM scaffold.  Implantation of these cell-assembled TEBVs in a canine model 
demonstrated tissue incorporation with intact endothelium, vasa vasorum, and an arterial 
media containing α-SMA positive SMCs as well as elastin and collagen.36  Mechanical 
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stability was demonstrated out to 8 months after implantation.  Implantation in a limited 
number of human subjects for hemodialysis access has demonstrated encouraging early 
results, although long-term aneurysmal dilatation has appeared to be a limitation of this 
strategy.37,38  Additionally, the significant time required for construction of these TEBVs, 
a common criticism for most TEBV construction strategies, have brought the real-world 
cost-effectiveness of this approach in question. 
Decellularized Vessel Scaffolds 
 Decellularized veins and arteries are a potential scaffold for TEBVs, and have the 
obvious advantage of possessing intact native vascular ECM structures.39,40  Animal 
experiments have demonstrated some success with this methodology.  Explanted 
decellularized grafts seeded with autologous ECs and implanted in animal models have 
demonstrated EC lined lumens at the time of explant with repopulating SMCs after four 
weeks.41,42  Of note, 89% of grafts seeded with ECs prior to implantation remained patent 
at four weeks, with only 29% of unseeded grafts remaining patent over the same time 
period.  A decellularized cryopreserved human vein allograft which was seeded with 
autologous ECs in a bioreactor was implanted in a human patient for iliac vein 
reconstruction.  This demonstrated the feasibility of this approach, although the tissue 
engineered graft failed after 4 months, reportedly secondary to progression of disease.43  
 Each of these strategies is associated with their own unique set of advantages and 
disadvantages.  The interest of our lab is that of promoting the growth of a 
microvasculature within the wall of a hydrogel-based TEBV as a functional vasa 
vasorum.   Our overall project hypothesis is that TEBVs of sufficient thickness to 
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withstand arterial pressures, as in native vessels, will require a vasa vasorum to provide 
nutritional and oxygen support to cells in the outer 1/3-2/3 of the blood vessel wall.  The 
studies described are intended to model this process utilizing fibrin, one scaffold of 
interest for our lab. 
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CHAPTER TWO 
ENGINEERING ANGIOGENESIS 
Angiogenic Vascularization of Tissue Engineered Organs 
 The study of angiogenesis has clinical applications in numerous fields including 
peripheral and coronary vascular disease, oncology, hematology, wound healing, 
dermatology, ophthalmology, and many others.  Experimental evidence demonstrates that 
the promotion of angiogenic processes can have potential therapeutic benefit in ischemic 
tissue, while the study of anti-angiogenic therapies have yielded several FDA approved 
additions to chemotherapeutic regimens in the field of oncology.44   
 In tissue engineering, the survival of thicker constructs will likely require either a 
microvascular network during development or the ability to rapidly foster neovascular 
ingrowth from a pre-existing vasculature after implantation.(Black et al., 1998)45,46 The 
observation that metabolically active cells cannot survive >100-200µm (the distance 
depending primarily on cell type) from their nutrient source is consistent with this 
hypothesis.(Folkman and Hochberg 1973)  As a result of this critical limitation, successes 
in tissue engineering have resulted in relatively thin and simply organized implants.  In 
addition, more complex organs containing segmental specialized native vascular supplies 
such as the liver, for example, will in turn require increasingly sophisticated 
vascularization methods during organ construction.  Thus, the study of angiogenesis and 
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the development of strategies which allow for precise control of angiogenic mechanisms 
within tissue engineered constructs has broad applications in the field of tissue 
engineering.  The studies in this dissertation are meant to model angiogenic processes 
which occur within the wall of a fibrin hydrogel based tissue engineered blood vessel 
during the engineering of a TEBV vasa vasorum. 
Vascularization for Tissue Engineered Blood Vessel Viability 
 The ex vivo development of a 3-D vascular conduit resembling a native vessel 
which can be utilized as an alternative for synthetic bypass grafts in vasculopathic 
patients, as a model for studying vascular biology, or as a conduit for other more complex 
tissue engineered organs is of great interest in tissue engineering.  Although progress has 
been made, this endeavor continues to present significant challenges.  Chief among these 
is that TEBVs thick enough to withstand arterial physiologic pressure will likely need a 
mature and functional microvasculature akin to a vasa vasorum in order to meet the 
metabolic and gas exchange requirements of SMCs in the outer two thirds of the arterial 
media.  A normal artery, usually greater than 1mm in thickness, requires the presence of a 
vasa vasorum through the outer two-thirds of the arterial media because diffusion of 
oxygen and nutrients from intraluminal circulating blood can only efficiently support the 
inner 100-200 µm of the arterial media.  It is logical, then, that for the development of a 
sufficiently thick conduit able to withstand arterial pressures (at least 1mm wall thickness 
in the published reports), the growth and maturation of a vasa vasorum with subsequent 
inosculation with the host capillary system will be essential to long-term functionality 
and viability of a TEBV.  This is further supported by several observations: 1) with the 
16 
 
 
exception of a handful of tissues, most cells within the body are no further than 200µm 
from capillary support; 2) removal of peri-aortic fat (with vasa vasorum) decreases aortic 
distensability, increases medial necrosis, and causes alterations in elastic fibers and the 
collagen/elastin ratio;47 and 3) arterialized vein grafts without vasa vasora support have 
documented hypoxia in the middle portion of the vessel’s cross-sectional thickness.48 
These observations and others have led us to develop the overall hypothesis that the 
presence of a prevascularized structure will have the benefit of promoting the viability of 
TEBV SMCs after implantation with earlier inosculation within the host circulation.  
Engineered Vasa Vasorum as a Source of Intimal Development  
In addition to its benefits on TEBV viability, we hypothesize that the presence of 
microvascular networks within the wall of a TEBV would have the secondary benefit of 
promoting a more durable construct by serving as a source of a viable endothelium at the 
luminal surface.  A quiescent endothelial monolayer provides a non-thrombogenic and 
mechano-transductive surface which is thought to be critical in the prevention of 
synthetic SMC activity which leads to the intimal hyperplastic response after vascular 
injury (Figure 2).1 This effect is partially dependent on the phenotypic characterization of 
the endothelium, however, as an endothelium activated by injury may function to 
promote thrombosis or intimal hyperplasia by the upregulation and release of adhesion 
receptors, vWF, tissue factor, endothelin-1, PDGF, and other EC products.49,50   
 Thus, it is believed that the induction of endothelialization on biomaterial blood-
contacting surfaces is critical in establishing the long-term biocompatibility of both 
vascular grafts and tissue engineered blood vessels, and it is likely that the inability of  
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Figure 2. EC coverage and SMC proliferation. SMC proliferation decreases with 
increased percent re-endothelialization in vivo using a canine carotid artery balloon 
angioplasty model.1 
humans to promptly generate a quiescent functional endothelium and establish normal 
histological archeology in the coronary and peripheral vascular system after graft 
implantation or intravascular intervention impacts the long-term patency of synthetic 
vascular prostheses.51     
 This phenomenon is not simply a function of insufficient EC proliferation, as the 
cessation of EC ingrowth approximately 1-3 cm from the edges of vascular anastomoses 
is seen even in the presence of elevated EC mitotic activity at these points on standard 
ePTFE grafts (30µm internodal distance) implanted clinically.52-54  Early observations in 
animal models suggested that ePTFE grafts with larger void spaces (60µm internodal 
distance) compared with standard ePTFE (30µm internodal distance) demonstrated 
increased EC coverage on the luminal surface.52  This has led to the general belief that a 
significant component of vascular endothelialization may result from transmural 
angiogenic mechanisms which consequently seed the luminal surface of the graft, in 
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addition to 1) the relatively limited spontaneous transanastomotic endothelial pannus 
ingrowth, and likely, 2) the deposition and differentiation of endothelial progenitor cells 
onto the de-endothelialized surface within the circulation.52,55-58   
               Strategies which can augment more rapid graft endothelialization in available 
and investigational prostheses will likely prove useful.59,60  These strategies can be 
broadly separated into two categories: 1) the in vivo augmentation of transmural 
angiogenesis, spontaneous anastomotic endothelialization, and endothelial progenitor cell 
(EPC) incorporation utilizing locally or systemically delivered drugs like angiogenic 
growth factors;61-64 and 2) the seeding of ECs or EPCs onto the graft surface via natural 
and synthetic polymeric coatings with or without adjunctive angiogenic growth factors 
prior to implantation.65-68   
 Thus, it is our belief that the prevascularization of tissue engineered blood vessels 
will serve to improve construct cellular viability within the arterial tunica media, provide 
for earlier inosculation with the host vasculature, and source an endothelial-lined intima.   
The Process of Angiogenesis 
 In order to construct a TEBV vasa vasorum (or a microvasculature of any tissue 
engineered organ), a major interest in many tissue engineering labs, including ours, is the 
modulation of angiogenic mechanisms within the scaffolding of tissue engineered 
constructs.  The delivery of natural and synthetic growth factors, modifications of genes 
and cell signaling pathways, and alterations in the extracellular matrix composition have 
been some of the strategies used in order to promote microvascular network formation.  
A discussion of the process of angiogenesis is thus critical in understanding the 
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fundamental strategies utilized in tissue engineering in order to optimize microvascular 
development (Figure 3). 
 
Figure 3.  Diagrammatic description of the steps involved in angiogenesis. A) A stable 
vascular structure comprised of an endothelial monolayer surrounded by mural tissue (i.e. 
basement membrane, pericytes, and adventitia); B) Destabilized vessel demonstrating the 
disruption of mural tissue by endothelial cells; C) Endothelial cell invasion into 
perivascular tissue and subsequent sprout formation; D) Endothelial cell lumenogenesis 
and tube formation with inosculation (not shown) to other pre-existing vascular 
structures; E) Stabilization of the capillary sprout by recruitment of pericytes and 
deposition of basement membrane.8 
New blood vessel formation, or neovascularization, occurs either by angiogenesis 
or by vasculogenesis.  Vasculogenesis occurs primarily in utero and in select situations in 
adults such as during tumor growth, myocardial revascularization, and endometriosis.  It 
is the creation of new vessels de novo from precursor cells, such as angioblasts, which 
differentiate into endothelial cells (ECs), form lumens, and create primitive blood vessels.  
In contrast, angiogenesis is the formation of new capillaries from the preexisting 
vasculature.  Arteriogenesis, or collateralization, results from the hypertrophy and 
luminal distention of preexisting vessels in response to mechanical stresses caused by 
redirected blood flow from occluded or stenosed distal vessels, mediated in part by 
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mechanosensitive signaling in vascular wall cells and by macrophage-derived 
biomolecular signals.69   
 The process of angiogenesis involves a complex and dynamic interaction between 
ECs and the corresponding extracellular environment.  In vivo, angiogenesis occurs either 
by the sprouting of vascular ECs from pre-existing capillary endothelia into the 
surrounding tissues, or by intussusception (aka non-sprouting angiogenesis), which 
involves the division of capillaries by tissue pillars into two or more daughter vessels.70,71  
The distinctions made between sprouting and non-sprouting angiogenesis, and the 
individual processes described below, may be somewhat arbitrary, as they all likely occur 
in concert and are regulated by related cellular and molecular mechanisms. 
Endothelial Cell Sprouting 
 In a normal blood vessel, a 100-200 ηm thick basement membrane (BM) lies 
immediately deep to the EC monolayer in the arterial intima.  Composed mainly of 
laminins, type-IV collagen, type-VIII collagen, and proteoglycans, the BM must be 
degraded prior to EC invasion into the surrounding ECM, which itself is comprised of 
fibrillar collagens, elastins, and various other ECM proteins.72  ECs, in response to 
angiogenic stimuli, convert from a quiescent to a synthetically active phenotype 
characterized by a high mitotic index and increased capacity for migration and matrix 
proteolysis.  These activated ECs are capable of disrupting the tight junctions, adherens 
junctions and gap junctions which exist between neighboring intimal ECs and 
perivascular cells, and invade into the BM and surrounding ECM.70,73  Once freed from 
the capillary intima and in the extravascular space, ECs proliferate and migrate towards 
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chemotactic and angiogenic stimuli in a 3-D extracellular environment and form new 
angiogenic sprouts. 74 
Lumenogenesis and Tubulogenesis 
 Lumen formation (and subsequent tube formation) can be considered a hallmark 
of angiogenesis as it is a relatively specific behavior attributed mainly to cells of the 
epithelium and endothelium.  It is the genetically programmed capacity of ECs to create 
luminal compartments within multicellular chains which allows for the flow of blood 
from the pre-existing vasculature to the neovasculature, without which new capillary 
networks would be unable to perform their central function of oxygen and nutrient 
transport to normal or pathologic tissues.  Indeed, one of the earliest demonstrations of 
angiogenesis in vitro by Folkman and Haudenschild provided evidence that, in the 
presence of “direct” angiogens, ECs in culture form capillary-like structures with 
rudimentary luminal compartments.75   
 While several mechanisms for lumen formation have been suggested, the most 
widely investigated mechanism is the process of intracellular vacuolization (or 
intracellular canalization).  The earliest observations of angiogenesis described the 
presence of “seamless” EC lined capillary lumens in vivo which were lacking in apparent 
cross-sectional EC-EC junctions.76,77  Since then, several in vitro and in vivo studies have 
provided for a mechanistic model of lumen formation consistent with this observation.  
Mediated by the α2β1 integrin and members of the Rho GTPase family, ECs undergo 
pinocytosis, leading to the formation of intracellular vacuoles which coalesce and form 
one larger intracellular lumen.78-83  This would explain the appearance of “seamless” EC 
22 
 
 
lined capillary lumens lacking apparent junctional contacts among several lumen lining 
cells.  The association of caveolin-1 expression, a protein involved in receptor mediated 
endocytosis and the formation of caveolae (cellular invaginations which often precede 
vacuole formation), with EC lumenogenesis is an interesting observation in light of this 
mechanistic hypothesis.84  Concurrently, cytoplasmic projections have been suggested to 
sense and form junctional contacts with neighboring ECs to thereby form more complex 
multicellular capillary tubes.82  
 While intracellular vacuolization is the most widely studied model of lumen 
formation in ECs, there are descriptions of other mechanisms.  These include 
intussusception, or the insertion of tissue pillars into the newly forming capillaries,85 
autophagy by lysosomes within individual ECs which leave behind luminal structures,86 
trans-luminal ingrowth of cytoplasmic filopodial projections which create a network of 
luminal structures,83 as well as the exocytosis of vacuoles between two (or more) ECs 
which are sprouting in close apposition to one another to form intercellular lumens 
(intercellular canalization).78,80  Other groups have proposed that apoptosis of centrally 
located ECs within a cluster of many ECs can lead to tubular neovascular structures.87,88  
This is consistent with data that demonstrates deficiencies in embryologic lumen 
formation and microvascular development in transgenic mice which conditionally 
express the anti-apoptotic protein Bcl-2 in ECs.89 
 It is important to note that these processes are often described or observed using 
in vitro assays of angiogenesis, and that the translation of these finding to the modeling of 
physiologic lumen formation in vivo is challenging.90   Nonetheless, these models of 
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angiogenesis are invaluable in attempting to understand the basic cellular and molecular 
mechanisms regulating lumenogenesis and angiogenesis in general.  It is also important 
to note that while the above mechanisms for lumen formation have been proposed as 
separate entities, they may in fact all be contributing to EC lumen formation 
concurrently, and the relative importance of any one particular mechanism may be 
dependent on factors such as the location of the cells undergoing lumenogenesis (i.e. the 
sprouting tip vs. the trunk/stalk of the sprout).91  It has also been proposed that 
heterogeneous populations of ECs with different functional characteristics can contribute 
to lumen and tube formation simultaneously.  Meyer et. al. suggested a model of 
angiogenic tube formation which relies on three different populations of ECs: 1) those 
with phagocytic functions which create matrix channels and later undergo apoptosis, 2) 
those which form vacuoles which coalesce and get exocytosed to the intercellular space 
leading to a primitive lumen which is subsequently remodeled, and 3) those which are 
added into the capillary tube at the final stage of angiogenesis and aid in lumen growth 
and remodeling.92 
 A further consideration is the temporal relationship of lumen formation to 
sprouting.  Whether one precedes the other, or, as suggested above, these processes occur 
simultaneously, is not entirely clear.  There is experimental evidence to suggest both 
possibilities.  Davis and Camarillo have demonstrated that vacuoles can be visible in ECs 
which are actively sprouting,81 while other studies demonstrate that branching and new 
sprout formation can occur in the absence of lumen formation.93,94   
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Cell-Cell Interactions 
 Perivascular cells such as pericytes (aka mural cells), SMCs, and adventitial 
fibroblasts, are associated with the endothelium of capillaries and are known to be 
involved in the later stages of angiogenesis during vessel maturation and stabilization 
(discussed below).  However, these primarily mesenchymally derived cells surrounding 
the endothelium also appear to have a significant role in mediating the early events of 
active angiogenesis.95-98  Secreted VEGF or deposited ECM proteins such as fibronectin 
by SMCs and fibroblasts in vitro have been demonstrated to elicit angiogenic activities 
such as  increased plasminogen activity, proliferation, motility, and cordlike structure 
formation in co-cultured ECs.99-104  Evidence that these paracrine interactions may be 
regulated by the local extracellular environment is provided by the observed endothelin-
1-mediated activation of EC mitogenesis by fibroblasts,100 and the production of Ang-2 
and VEGF in mesangial cells (renal pericytes) under hypoxic conditions.105  In vivo 
observations of pericytes found “leading” angiogenic sprout tips and lining vascular tubes 
connected to tumor vasculatures which lack ECs in vivo suggest a more direct role for 
pericytes as guiding cells during angiogenesis.106,107  These data are consistent with 
observations that under hypoxic stimulation, VEGF-secreting perivascular cells appear to 
be the first vascular cells to invade the corpus luteum parenchyma during ovulatory 
angiogenesis.108  Thus, while the later stabilization and maturation of the 
microvasculature by pericytes is well established, the likelihood that they promote 
angiogenesis given the proper pro-angiogenic environmental context suggests a more 
broad role for these cells which warrants further study.109   
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Inosculation 
 Inosculation is the fusion or anastomosis of two vascular lumens or luminal 
segments to form one continuous lumen.  Although an understudied process in 
angiogenesis, some literature from the field of skin graft vascularization can be 
extrapolated to provide some insights into this later step of angiogenesis.  In 1980, 
Tsukada demonstrated that the preservation of the subcutaneous vascular network of a 
skin graft facilitated free tissue transfer, and that this was associated with both the 
formation of a neovasculature, as well as the inosculation between the preexisting host 
and donor vasculature.110  By analyzing the establishment of donor/host vascular 
continuity in grafted skin, studies have demonstrated that skin neovascularization with 
complete inosculation occurs between three to seven post-operative days following skin 
grafting.111,112  Immunohistochemical staining of human skin transplanted onto athymic 
mice has documented recipient EC invasion into the graft between days 3 and 21 via 
neovascularization with blood flow commencing on days 3-7.    Of note, recipient beds 
were not seen to have donor EC ingrowth.113  The molecular mechanisms involved in 
inosculation, however, are still relatively unknown, and further study of this phase of 
angiogenesis is required. 
Pericytes 
 The recruitment and incorporation of pericytes are key events which mediate the 
final steps required for the stabilization and maturation of the neovasculature.73  Pericytes 
are primarily thought to be derived from cells of mesenchymal origins such as SMCs, 
fibroblasts or other progenitor cells and possess markers such as α-actin, desmin, PDGF-
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β receptor, and NG2 which are common to those cells.73,97,114  Several lines of evidence 
support the role of pericyte incorporation for the stabilization of neovessels and the 
regulation of uncontrolled angiogenic growth.  Early studies showed that mice lacking 
the ability to recruit pericytes during embryonic vascular development demonstrated 
increased vessel microaneurysm formation and rupture.115  Generally speaking, abnormal 
pericyte coverage and function in the microvasculatures of certain types of tumors is 
associated with increased EC sensitivity to VEGF withdrawal116-120 and 
microvasculatures with disrupted EC/pericyte interactions are associated with more 
dynamic remodeling.121   
 Direct contact via gap junctions, adhesion plaques, and adherens junctions, as 
well as indirect paracrine mechanisms between ECs and pericytes, allow for significant 
interactions which impact cellular differentiation, migration, proliferation, and 
quiescence.122-125  Among the paracrine mediators, PDGF is thought to be critical in the 
recruitment and proliferation of pericytes during angiogenesis.  PDGF is a mitogen and 
chemoattractant for fibroblasts, SMCs, and other mesenchymal cells which is present in 
four known isoforms A, B, C, and D (with the A and B isoforms most notably studied in 
the literature in relation to the recruitment of pericytes during angiogenesis, and to the 
migratory and proliferative behavior of smooth muscle cells).  Two known PDGF 
transmembrane receptor tyrosine kinases known as the α and β subunit bind each chain 
with relative specificity (the α receptor binds the A, B, and C chains primarily while the β 
receptor binds the B and D chains).  Because PDGF exists as a hetero- or homodimer, 
ligand binding causes receptor hetero- or homodimerization (i.e. PDGF-BB and PDGF-
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AB can bind α/α, α/β, or β/β, while PDGF AA binds α/α exclusively) and subsequent cell 
signaling.126-128  As PDGF-β is the primary receptor present on SMCs and other pericytes, 
PDGF-B/β signaling is especially critical in the proper recruitment of pericytes to 
capillaries.   Disrupted PDGF-B/β signaling is associated with the attenuated ability to 
recruit PDGF-β receptor positive pericytes and precursors from the perivascular tissue 
and the bone marrow and is associated with significant vascular abnormalities in 
physiologic and pathologic angiogenesis.115,118,129-134  
 The source of PDGF during this process is likely from actively angiogenic ECs 
themselves, which suggests an inherent negative feedback mechanism to prevent 
uncontrolled neovascularization.73  Proliferative ECs in vitro are potent stimulators of 
pericyte/SMC growth and migration, in part mediated by PDGF-BB, although this effect 
is dependent on the time in co-culture, the presence or absence of direct contact, and the 
deposition of endothelial-specific ECM proteins.135-143  The importance of EC-specific 
PDGF-B production in pericyte recruitment in vivo was demonstrated in studies which 
showed that EC-specific knockout of PDGF-B led to significant vascular abnormalities 
with pericyte loss in mice.144-146   
 Clinically, the simultaneous targeting of pericytes and ECs by pro- or anti-PDGF 
and VEGF therapy, has been investigated in tissue engineering and oncologic research.  
Combination therapy (manipulating both PDGF and VEGF) has been shown in some 
studies to be more effective in disrupting tumor vascularity than either agent alone and, 
as such, combinatorial antitumor therapy is under investigation.147-150  It is unclear, 
however, if the apparent improved anti-angiogenic effect observed in combination 
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therapy is specifically attributable to PDGF blockade or to the broad non-specific effects 
of the receptor tyrosine kinase inhibitors used in most studies of combination therapy.  
Recently, it was shown that adenoviral expression of soluble anti-PDGF-β receptor 
provided added inhibition of tumor growth and angiogenesis only when sub-optimal 
levels of VEGF blockade were present.151  Clearly, however, PDGF signaling does 
impact angiogenesis in vivo, as the spatiotemporal delivery of PDGF with VEGF has 
been shown to induce denser and more mature appearing vascular networks within tissue 
engineered constructs, which is in part associated with the recruitment of α-actin positive 
(indicative of pericytes) cells into the neovascular networks.152,153   
 Although the expansion, spreading, and migration of the SMC/pericyte population 
on newly formed capillaries may be dependent on PDGF-B/β signaling, it does not 
appear to be sufficient or necessary for the phenotypic differentiation of undifferentiated 
mesenchymal cells to pericytes.  Instead, this appears to be significantly regulated by 
TGF-β,131,154 as evidenced by observations that ECs direct 10T1/2 cells (a cell line 
commonly used to model pericyte precursor cells in vitro) to an SMC/pericyte phenotype 
via a TGF-β-mediated mechanism,141,155 and that the phenotypic differentiation of SMCs 
in co-culture with ECs involves activation of the SMC PI3-K/Akt pathway, which may be 
mediated by TGF-β.156,157   
 With these above observation taken together, it has been proposed that two modes 
of pericyte incorporation occur simultaneously: 1) the differentiation of undifferentiated 
mesenchymal and progenitor cells into pericytes; and 2) the recruitment and co-migration 
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of differentiated mesenchymal cells such as SMCs from a pool of available cells in the 
perivascular tissue into neovessels.131 
 It is believed that once incorporated, a major function of pericytes is to mediate 
the quiescence of ECs.  In vitro, ECs in direct contact with pericytes have lower levels 
mitosis compared to ECs cultured alone, a process which may require Rho GTPase 
activity in pericytes.142,158,159  Similarly, ECs in close contact with SMCs in a spherical 
aggregate of SMCs in collagen gels demonstrated decreased responsiveness to VEGF (in 
the absence of Ang-2), increased inter-endothelial junctions, decreased PDGF-B growth 
factor chain expression, and reduced apoptosis.160  ECs in co-culture with 10T1/2 cells 
also displayed a significantly higher resistance to the permeability of a tracer molecule 
biotin-dextran which was associated with tightening of EC-EC tight junctions and with 
the localization of tight junction proteins plakoglobin, ZO-1, ZO-2, and occludin.161   
 It has also been suggested that pericytes induce vessel stabilization by the 
production of survival factors.  This is supported by several lines of evidence: 1) neonatal 
vessels which are resistant to oxygen-induced degeneration are associated with pericytes 
which express TGF-β1, which induces VEGFR-1 expression in ECs;162 2) 10T1/2 
precursor cells produce VEGF upon TGF-β-mediated conversion to pericytes when in 
direct contact with ECs;163 3) pericytes express Ang-1 in vitro and in vivo, a growth 
factor which is associated with basement membrane formation, EC quiescence and 
endothelial leak resistance, and which can mature vessels lacking pericytes;164-167 and 4) 
pericyte loss caused by PDGF inhibition in a rat model of retinopathy results in 
overexpression of VEGF/VEGFR2 in ganglion cells and other supporting cells.168 
30 
 
 
 A final mechanistic hypothesis for the pericyte-mediated regulation of 
angiogenesis is that pericytes significantly modulate the ECM remodeling capacity of 
ECs by directly influencing the local ECM composition.  Pericyte-conditioned media has 
been shown to limit both EC migration and branching in vitro by inducing the 
upregulation of PAI-1 in ECs.169  In addition, pericytes have been shown to produce 
TIMP-3 and induce TIMP-2 production in ECs, which specifically targets MT1-MMP, 
MT2-MMP and ADAM (a disintegrin and metalloprotease) proteinases, with the net 
effect of decreasing angiogenic potential and tube regression.170-172  In addition, pericyte-
mediated ECM deposition, specifically the deposition and synthesis of basement 
membrane, has also been proposed to promote EC quiescence and vessel stability.173-175  
The importance of the basement membrane in vascular stability is demonstrated in 
laminin-8 knockout animals which demonstrate a poorly developed microvasculature 
with defective basement membranes, noticeable deformities, and increased 
responsiveness to pro-angiogenic stimuli.176  
 While the mechanisms discussed above in the maturation and stabilization of 
existing and newly formed vessels are still topics of current study, it is becoming clear 
that this final stage of angiogenesis is a significant contributor to the persistence and 
function of pathologic and physiologic neovasculatures, and will likely provide for future 
therapeutic strategies. 
Cell Signaling 
 The Aims of this proposal will address cell signaling processes, specifically those 
mediated by Notch, ERK, and Akt, as it relates to SMC/pericyte and EC interactions 
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during angiogenesis.  These pathways were chosen for their known importance in cell 
proliferation, migration, and survival, as well as in the mediation of inter- and 
intracellular signaling processes during angiogenesis.  More detailed discussions of these 
pathways and mechanisms will be described within the Aims of the proposal.    
 The remainder of the dissertation will focus specifically on the interaction 
between the SMCs and ECs within the wall of the TEBV during microvascular growth, 
hypothesizing that SMCs will function as pericytes in the engineered neovasculature.  
The studies and aims outlined below are intended to model these processes within a 
fibrin-based, or fibrin-containing TEBV, but can be applied more broadly to any 
hydrogel-based tissue engineered construct. 
Tissue Engineered Blood Vessel and Vasa Vasorum Construction 
 For the reasons discussed above, the studies and objectives detailed in this project 
are intended to model angiogenic processes occurring within the wall of a tissue 
engineered blood vessel during vasa vasorum development, and more broadly, during 
microvascular development in any hydrogel based or hydrogel-containing tissue 
engineered construct.  Specifically for the purposes of our lab, TEBV construction is that 
of a fibrin hydrogel-based strategy (Figures 4 and 5). 
Previously in our lab, the combination of VEGF-165 and FGF-1 was shown to 
synergistically augment angiogenic sprout formation from an aggregate of bovine aortic 
endothelial cells placed within fibrin hydrogels in a 3-D in vitro angiogenesis assay.177  
We utilize this strategy in order to increase EC sprouting potential during the 
construction of our TEBVs.    SMCs are first embedded within a solution of fibrinogen,  
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Figure 4.  TEBV Construction.  (A) A pre-polymerized fibrin hydrogel containing SMCs 
(not shown) are poured around a mandrel. B) EC aggregates polymerized within the 
hydrogel.  C) ECs form microvasculatures. D) Final structure.3   
 
Figure 5.  Creation of TEBV.  By 4 days of static culture, compaction of the hydrogel 
around the central mandrel is noted.  On Day 7, the TEBVs are placed within a bioreactor 
chamber. 
heparin, VEGF-165 and FGF-2 (FGF-2, a more commonly studied FGF isoform, 
demonstrates grossly similar mitogenic and chemotactic stimulus for ECs and SMCs, and 
was chosen for these studies due to availability from commercial vendors), smooth 
muscle cells and culture media and poured into a tubular construct mold.  This serves as 
the foundation of the arterial tunica media.  Aggregated endothelial cells are mixed in the 
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fibrinogen based solution as a source of the microvasculature.  Finally, thrombin is added 
in order to polymerize the fibrinogen solution, leading to a tubular structure containing 
aggregated ECs with a fibrin-based scaffold containing homogenously distributed SMCs.  
A period of preconditioning in a bioreactor exposing the TEBV to 7 days of 10% cyclic 
volumetric distension, mimicking the pulsatile forces of the vascular system, allows for 
the improvement of mechanical properties prior to use in experiments or as a potential 
conduit.3,26,178  
 The specific Aims of this proposal focus on the interactions between SMCs and 
ECs during microvascular development in the TEBV tunica media.  The experiments 
described below utilize fibrin-based disks, instead of tubes, in order to simplify the model 
to focus specifically on the angiogenic process within the construct wall.  
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CHAPTER THREE 
AIMS 
 Capillaries are comprised of two cell types: the endothelial cells which line the 
lumen of the capillary, and the supporting pericytes which are closely apposed to the 
abluminal surface of the capillary wall (sometimes called mural cells; Figure 6). These 
pericytes are phenotypic derivations of mesenchymal organ stromal cells (from smooth 
muscle cells and fibroblasts in blood vessels, for example), are recruited and incorporate 
into the neocapillaries, and are known to mediate reciprocal interactions with ECs during 
angiogenesis.  They are not only considered necessary for the stabilization of the 
microvasculature in vivo but are also thought to be involved in the early formation of 
angiogenic networks.    
 
Figure 6.  Pericytes in capillaries.  Left) Pericytes are seen associated with the abluminal 
surface of a capillary comprised of 1-2 ECs.  Right) Depiction of pericyte recruitment by 
an angiogenic EC sprout. Modified from Armulik, et al.2 
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The creation of microvasculatures to feed the stromal cells of tissue engineered 
organs (i.e. SMC in TEBVs) is thought to be a critical need.  How these stromal cells in 
tissue engineered organs affect angiogenesis during organ and microvasculature creation, 
and the mechanisms underlying EC and pericyte interactions, are still a topic of 
considerable study.  In the following Aims and studies, we utilize SMCs as both the 
primary cellular component of the TEBV stroma, as well as the source for incorporated 
pericytes in our engineered TEBV microvasculatures.  Several lines of evidence support 
the role of pericyte incorporation for the stabilization of neovessels and the regulation of 
uncontrolled angiogenic growth.  Early studies showed that mice lacking the ability to 
recruit pericytes during embryonic vascular development demonstrated increased vessel 
microaneurysm formation and rupture.115  Generally speaking, abnormal pericyte 
coverage and function in the microvasculatures of certain types of tumors is associated 
with increased EC sensitivity to VEGF withdrawal116-120 and microvasculatures with 
disrupted EC/pericyte interactions are associated with more dynamic remodeling.121  In 
addition, pericytes appear to have a significant role in mediating the early events of active 
angiogenesis.95-98  Secreted VEGF or deposited ECM proteins such as fibronectin by 
SMCs and fibroblasts in vitro have been demonstrated to elicit angiogenic activities such 
as  increased plasminogen activity, proliferation, motility, and cordlike structure 
formation in co-cultured ECs.99-104  99-104  In vivo observations of pericytes found 
“leading” angiogenic sprout tips and lining vascular tubes connected to tumor 
vasculatures which lack ECs in vivo suggest a more direct role for pericytes as guiding 
cells during angiogenesis.106,107  These data are consistent with observations that under 
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hypoxic stimulation, VEGF-secreting perivascular cells appear to be the first vascular 
cells to invade the corpus luteum parenchyma during ovulatory angiogenesis.108   
 The overall purpose of this project is to determine how SMCs affect angiogenesis 
during microvascular development in fibrin hydrogels using 3-dimensional co-culture 
assays of angiogenesis.  These studies are meant to model angiogenic processes in the 
wall of a fibrin hydrogel based TEBV containing ECs and SMCs described above.  The 
overall hypothesis is that SMCs promote angiogenic network formation and persistence 
of microvasculatures in fibrin hydrogels and that this effect is modulated in part by a 
Notch dependent pathway.   
Aims 
Aim 1 
Quantify the effect of SMCs on the formation and persistence of engineered 
microvascular networks in fibrin hydrogels. 
The hypotheses are that: 1) Endothelial cells (ECs) will sprout from an aggregated 
spheroid of ECs and form angiogenic networks in the presence of SMCs in fibrin 
hydrogels; 2) SMCs will co-localize with angiogenic sprouts indicating incorporation into 
the neovasculature as pericytes; and 3) SMCs will  promote both angiogenic network 
formation and persistence during microvascularization of fibrin hydrogels. 
Rationale 
The microvascularization of tissue engineered organs is thought to be a critical 
need in tissue engineering.  Growth factors such as VEGF and FGF-2 are commonly 
utilized to augment the angiogenic processes required for construct microvascularization, 
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and are known to be important pro-angiogenic growth factors during angiogenesis in 
vivo.  Mesenchymally derived pericytes, such as those derived from SMCs (the stromal 
cells of tissue engineered blood vessels) may modulate the initiation and persistence of 
angiogenic networks by several potential mechanisms: 1) the production of soluble 
angiogenic factors, 2) the activation of cell-cell signaling pathways, and 3) the deposition 
and remodeling of the extracellular matrix surrounding neovasculatures.  The purpose of 
this Aim is to investigate how SMCs affect angiogenesis in the presence and absence of 
exogenous growth factors during microvascular development in fibrin hydrogels.   
Aim 2 
Determine how EC signaling pathways involved in angiogenic network formation 
(e.g. proliferation) and persistence (e.g. survival) are affected by co-culture with SMCs. 
Hypothesis: Co-culture with SMCs will activate ERK and Akt in ECs by the 
release of soluble angiogenic products. 
Rationale 
The co-culture of ECs with SMCs has the potential to alter EC proliferation and 
survival signaling pathways via the release of soluble factors, cell-cell signaling, or other 
mechanisms.  Previous work has demonstrated that SMCs can produce several growth 
factors including VEGF, angiopoietins, and others.  This Aim will investigate how 
soluble products released by SMCs affect the phosphorylation of Akt and ERK cell 
signaling pathways in ECs.   
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Aim 3 
Determine if Notch signaling mediates the SMC effects on angiogenesis in fibrin 
hydrogels.  
Hypothesis: Notch in ECs will mediate the angiogenic and signaling responses to 
SMC derived soluble factors.  
Rationale 
Notch is a known mediator of EC signaling and angiogenesis in response to 
growth factors such as VEGF.  In addition, Notch signaling affects pericyte recruitment 
and SMC migration, modulates pericyte and EC gene expression in co-culture systems, 
and may also be directly involved in cell-cell signaling pathways at points of EC and 
SMC contact.  This Aim will determine if Notch signaling is involved in the angiogenic 
processes during engineering of co-culture microvascular networks in fibrin hydrogels.  
Based on the results of the previous two Aims, these studies will specifically address the 
role of EC Notch activation in response to exogenous growth factors and to soluble 
products produced by SMCs.   
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CHAPTER FOUR 
THE EFFECTS OF SMCS ON ANGIOGENESIS  
IN FIBRIN HYDROGELS 
Introduction 
Pericyte-EC Interactions during Angiogenesis 
 Perivascular cells such as pericytes (aka mural cells), SMCs, and adventitial 
fibroblasts, are associated with the endothelium of capillaries and are known to be 
involved in the later stages of angiogenesis during vessel maturation and stabilization 
(discussed below).  However, these primarily mesenchymally derived cells surrounding 
the endothelium also appear to have a significant role in mediating the early events of 
active angiogenesis.95-98  Secreted VEGF or deposited ECM proteins such as fibronectin 
by SMCs and fibroblasts in vitro have been demonstrated to elicit angiogenic activities 
such as  increased plasminogen activity, proliferation, motility, and cordlike structure 
formation in co-cultured ECs.99-104  99-104 Evidence that these paracrine interactions may 
be regulated by the local extracellular environment is provided by the observed 
endothelin-1-mediated activation of EC mitogenesis by fibroblasts,{Davie, 2006 #1178} 
and the production of Ang-2 and VEGF in mesangial cells (renal pericytes) under 
hypoxic conditions.105  In vivo observations of pericytes found “leading” angiogenic 
sprout tips and lining vascular tubes connected to tumor vasculatures which lack ECs in 
vivo suggest a more direct role for pericytes as guiding cells during angiogenesis.106,107  
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These data are consistent with observations that under hypoxic stimulation, VEGF-
secreting perivascular cells appear to be the first vascular cells to invade the corpus 
luteum parenchyma during ovulatory angiogenesis.108  Thus, while the later stabilization 
and maturation of the microvasculature by pericytes is well established, the likelihood 
that they promote angiogenesis given the proper pro-angiogenic environmental context 
suggests a more broad role for these cells which warrants further study.109   
Pericytes and Vascular Maturation 
 The recruitment and incorporation of pericytes are key events which mediate the 
final steps required for the stabilization and maturation of the neovasculature.73  Pericytes 
are primarily thought to be derived from cells of mesenchymal origins such as SMCs, 
fibroblasts or other progenitor cells and possess markers such as α-actin, desmin, PDGF-
β receptor, and NG2 which are common to those cells.73,97,114  Several lines of evidence 
support the role of pericyte incorporation for the stabilization of neovessels and the 
regulation of uncontrolled angiogenic growth.  Early studies showed that mice lacking 
the ability to recruit pericytes during embryonic vascular development demonstrated 
increased vessel microaneurysm formation and rupture.115  Generally speaking, abnormal 
pericyte coverage and function in the microvasculatures of certain types of tumors is 
associated with increased EC sensitivity to VEGF withdrawal 116-120 and 
microvasculatures with disrupted EC/pericyte interactions are associated with more 
dynamic remodeling.121   
 The purpose of these studies is to investigate EC and SMC interactions utilizing 
novel 3-D co-culture assays of angiogenesis.  The SMCs in these experiments are 
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intended to act as both the stromal cells of a fibrin-based tissue engineered blood vessel 
as well as the source of pericytes of engineered neovasculatures. 
Materials and Methods 
Materials 
 Chemicals, biological reagents, and experimental supplies were obtained as 
follows: collagenase (Invitrogen); human thrombin (American Red Cross; Rockville, 
MD); FGF-2, VEGF (R&D Biosciences); Mitomycin C, L-ascorbic acid, 
methylcellulose, fibrinogen, transferrin, insulin, anti–α-actin antibody and aprotinin, anti-
VWF antibody, PKH-27, PKH67 (Sigma Chemical Co.; St. Louis, MO); tritiated 
thymidine (NEN Life Science Products; Boston, MA); methanol, trichloroacetic acid, 
acetic acid, and scintillation fluid (Fisher Scientific; Fair Lawn, NJ); bovine lung heparin 
(Upjohn; Kalamazoo, MI); Calcein AM (Molecular Probes, Eugene, Ore); 0.05% 
trypsin/EDTA, HBSS, M199, DMEM, L-nonessential amino acids, sodium pyruvate, 
penicillin, streptomycin, DMEM-F12 (Gibco, Grand Island, NY); fetal bovine serum 
(FBS) (Hyclone, Logan, UY); woven nylon mesh rings (ID = 7.5 mm, OD = 13 mm) 
(Sefar America Inc; Kansas City, MO); Parafilm M (American National Can, Greenwich, 
CT); 100-mm and 60mm Petri dishes (Fisher Scientific; Pittsburgh, PA); 24 wells plates 
and tissue culture flasks, Costar Transwell polystyrene plates (Corning Costar Corp; 
Cambridge, MA); round bottom 96 well plates (Greiner Bio-one; North Carolina); 96-
well polystyrene plastic plates (Beckton Dickinson; Lincoln Park, NJ).  
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Animal Care 
 All animal procedures complied with The Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, Commission of Life 
Sciences, National Research Council, 1996) and The Principles of Laboratory Animal 
Care (National Institutes of Health publication no. 85-23, revised 1985) and were 
approved by our institutional IACUC. 
Cell Isolation 
 SMCs and ECs were harvested from canine carotid arteries and jugular veins, 
respectively per previously published protocols.179,180 Briefly, adult mongrel dogs were 
anesthetized with thiopental sodium, intubated, and ventilated.  Anesthesia was 
maintained with nitrous oxide and methoxyflurane.  Bilateral neck incisions were made.  
 For ECs, bilateral external jugular veins were removed, inverted, and processed 
per our previously reported protocol beginning with the veins being sequentially placed 
into 0.05% trypsin/EDTA 0.53 mmol/L and collagenase 100 U/mL at 37°C for 10 
minutes each.  Next, the veins were discarded, and the trypsin and collagenase solutions 
were centrifuged.  The subsequent pellets were resuspended in EC complete medium 
supplemented with FGF-1 (5 ng/mL), and the ECs were plated onto a fibronectin-coated 
(2.5 µg/cm2) T-25 culture flask that was incubated in a 37°C, 5% carbon dioxide 
chamber. The media was changed every 2 to 3 days, and confluent cells were passaged 
with trypsin-EDTA.   EC identity was confirmed using immunofluorescent dual staining 
with anti-vWF and anti-α-actin antibodies.  Only EC exhibiting 95% positive vWF 
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staining and 2% or less α-actin staining were used for the proliferation assays. ECs were 
used within passages 1 to 5. 
 For SMCs, the carotid arteries were opened longitudinally, and the intima and 
adventitia were removed by sharp dissection. The medial layer was minced and placed 
into SMC growth media.  Primary SMCs migrating from the explants were used in all 
experiments.  SMC identity was confirmed by immunofluorescent staining with anti-α-
actin antibodies, and only cultures exhibiting 95% positive staining were used in the 
assays.  Individual carotid artery explants were used as the source of cells for assays no 
more than 3 times.  
Mitomycin C Treatment 
 In experiments using Mitomycin C (MMC) treatment to inhibit cell proliferation, 
500,000 SMCs were plated onto 60mm Petri dishes and treated with 10 µg/mL of MMC 
for one hour prior to use in experiments.  SMCs which were plated, but not treated with 
MMC, served as controls.   
Methocel Preparation 
 Methylcellulose reagent (1.2 g) was autoclaved in a 250-mL beaker at 120°C for 
20 minutes. The autoclaved powder was dissolved in 50 mL of preheated (60°C) M199, 
stirred at 60°C for 20 minutes, and then 50 mL of M199 at room temperature was added. 
The solution was mixed for 2 hours at 4°C, centrifuged for 2 hours at 4,000 rpm, and the 
supernatant was collected after centrifugation. 
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Angiogenesis Assays 
Co-Culture Assay 1: Angiogenesis in the Presence of Homogenously Distributed SMCs 
 SMCs were fluorescently labeled green with PKH-67 (10 µM) and ECs were 
fluorescently labeled red with PKH-26 (10 µM) per manufacturer instructions.   PKH is a 
cell membrane label  which incorporates into the plasma membrane of cells and is 
divided equally into subsequent progeny cells.181  Fibrin hydrogels were constructed by 
preparing a fibrinogen solution consisting of fibrinogen (2.5 mg/mL), M199, heparin 
(5U/mL), and green fluorescently labeled SMC.  The solution was polymerized by the 
addition of thrombin (0.32U/mL) (Figure 7). 
 
Figure 7.  Technique of co-culture assay #1.  SMC (green with blue outline) containing 
fibrin hydrogel layer is plated on a 96 well flat bottom plate.  Fluorescently labeled 
aggregate of ECs (red) are placed on top of gel and covered with second fibrin hydrogel 
containing SMCs and then cultured in angiogenesis assay media. 
Red fluorescently labeled ECs, 10,000-20,000, were suspended in an aggregating 
solution consisting of angiogenesis assay media (see appendix) and a 20% methocel 
solution182 into each well of a round bottom 96-well plate and incubated at 37°C for 24 
hours until cell aggregates formed.  ECs were embedded between two layers of fibrin 
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gels in the wells of flat-bottom 96 well plates.  In experiments with higher concentrations 
of SMCs followed for longer periods, the hydrogels were polymerized onto nylon mesh 
rings to minimize the impact of SMC-mediated gel contraction and then cultured in 24 
well plates.  EC aggregates embedded within hydrogels that did not contain SMCs served 
as controls.  Angiogenesis assay media was added to the top of the hydrogels containing 
the cells, and the assays were incubated at 37°C.  In experiments testing the effects of 
growth factor addition and withdrawal, VEGF and FGF-2 were added to the 
prepolymerized hydrogel as well as the assay media to achieve a final concentration of 
10ng/mL for each growth factor in both the media and the hydrogel.  After a period of 
time, ECs invade from the central aggregate into the surrounding hydrogel.  Digital 
images were taken daily for up to 13-17 days at a magnification of 4x using a Zeiss 
Axiovert 200M microscope (Carl Zeiss, Inc, Oberkochen, Germany) and Axiovision 
software.  The digital photographs were aligned with a grid evenly divided in 36 radial 
intervals using Adobe Photoshop for quantification using both TRITC and FITC filters.  
For each assay, the average length of sprouts (ALS) was determined by measuring the 
furthest point on each grid line with an invading chain of cells.  A secondary data point 
quantifying the density of sprout formation (DSF) was also measured by calculating the 
number of grid lines with crossing sprouts/36 total grid lines (Figure 8). The presence of 
cellular debris and discontinuity of previously continuous chains of invading cells is 
indicative of cell death.182  For this reason, invasion was quantified by measuring only 
out to the final point of a continuous chain of cells.  Data from three individual 
experiments were pooled and presented +/- SEM. 
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Figure 8.  Quantification of angiogenesis.  ALS=Average length of sprouts; DSF=Density 
of sprout formation; L=Length; R=Radius of EC pellet. 
Histology 
 At the end of selected assays, representative angiogenesis assay hydrogels were 
processed for cross-sectional morphologic analysis with transmission electron 
microscopy.  The assay disks were fixed with a 1% glutaraldehyde/4% paraformaldehyde 
solution, postfixed in 1% osmium tetroxide, dehydrated in a graded series of acetone, and 
embedded in epoxy resin.  Ultrathin sections were cut, collected on copper grids, and 
stained with uranyl acetate and lead citrate.  The sections were viewed on a transmission 
electron microscope (H-600; Hitachi, Tokyo, Japan) at 75 kV.  
Co-Culture Assay 2: Direct Contact Co-Culture Angiogenesis Assay 
2250 green fluorescently labeled SMCs were suspended in an aggregating 
solution consisting of angiogenesis assay media and a 20% Methocel solution182 and 
added into each well of a round bottom 96-well plate and incubated at 37°C for 24 hours 
until cell aggregates formed (Figure 9).  After 24 hours, 350 red fluorescently labeled 
ECs were added to each well and allowed to seed the surface of the SMC aggregate.  In 
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experiments which tested the effects of inhibiting SMC proliferation on EC matrix 
invasion, ECs were seeded onto aggregates of SMCs which were either treated or 
untreated with MMC as described above.  The co-culture aggregates were then embedded 
between two 150 µL layers of fibrin that were polymerized on a nylon mesh ring such 
that the aggregates were completely surrounded by the hydrogel.  Once completely 
polymerized, the disks were transferred into 24 wells plates and cultured in angiogenesis 
assay media at 37°C.  After a period of time, SMCs and ECs invade from the central 
aggregate into the surrounding hydrogel (Figure 10). Digital images were taken daily for 
up to 19 days at a magnification of 4x and quantified as described above.  Each 
individual experiment was analyzed by Student’s T-test with an α of 0.05 with 
statistically consistent results.  Data from a representative experiment is presented in the 
results. 
 
Figure 9.  Coculture assay #2.  SMCs green are aggregated in a methylcellulose 
containing solution and seeded with ECs (red).  The co-culture aggregated is then 
embedded between two layers of fibrin and cultured in angiogenesis assay media. 
Statistical Analysis 
 We used analysis of variance with Tukey posttests or Student’s T-tests using 
SigmaStat (Systat Software Inc, San Jose, CA) at an α of 0.05 to determine statistical 
significance. 
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Figure 10.  Co-culture aggregate assay.  Left) Fluorescently green labeled SMC 
aggregate. Middle) Fluorescently labeled red ECs coating SMC aggregate.  Right) 
Merged image of red ECs covering the surface of the green labeled SMC aggregate. 
Mag.10x. 
Results 
Coculture Assay 1 
Morphology   
 Fluorescent microscopic evaluation of angiogenic sprouts demonstrated 
endothelial cell sprouts radiating from the central aggregate into the hydrogel matrix.  
Fluorescently labeled SMCs were found to closely associate with both the EC aggregate 
as well as individual endothelial cell sprouts (Figure 11).  
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Figure 11.  Sprouting from co-culture assay #1.  Left) Fluorescently labeled green SMCs 
are homogenously suspended within the fibrin hydrogel.  Middle) Fluorescently red 
labeled ECs are seen sprouting from a central aggregate of ECs into the matrix.  Right) 
Merged image of ECs sprouting into the ECM containing SMCs which associate with EC 
sprouts. Mag 10x.  (Lower image) Digital zoom of merged image. 
Cross-sectional morphology of angiogenic sprouts examined under transmission 
electron microscopy after the 13 days demonstrated luminal structures surrounded by 2-3 
endothelial cells which were closely associated by smooth muscle cells on the abluminal 
surface (Figure 12). The sprouts and associated cells were completely surrounded by the 
fibrin extracellular matrix.  Debris was present within the lumen of the sprouts in each of 
the sections.   SMCs within the matrix seen in sections lacking angiogenic sprouts did not 
form luminal structures (not shown).  
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Figure 12.  Cross sectional morphology of co-culture sprouts by transmission electron 
microscopy.  Selected images demonstrate EC lined luminal structures with SMCs 
apposed to the abluminal surface of the capillary.  The structure is surrounded by the 
fibrin matrix. ECM = extracellular matrix; L = Lumen; Arrows = SMCs; Arrowheads = 
ECs.  
Angiogenesis in Response to Growth Factors 
The effects of SMCs on the angiogenic response to VEGF and FGF-2 in 
combination was determined (Figure 13). Angiogenesis was quantified in the presence 
and absence of SMCs at concentrations of 0, 2500, 7500, 22,500, 67,500 SMCs/mL.  At 
Day 3, the average length of sprouts (ALS) in ECs cultured in the presence of VEGF and 
FGF-2 was 331 +/- 10 µm vs. 209 +/- 10 in ECs cultured in the absence of growth factors 
(p <  0.001).  At Day 3 in the presence of growth factors, the ALS of EC sprouts co-
cultured in the presence of any concentration of SMCs did not significantly differ from 
the ALS of EC sprouts cultured in the absence of SMCs (p=.19). 
Angiogenesis after Growth Factor Withdrawal 
To model the effects of SMCs on angiogenesis after the withdrawal of angiogenic 
growth factors, angiogenesis was quantified after 3 days of culture in the presence of 
L 
L 
EC
EC
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VEGF and FGF-2, and then quantified up to 13 days after withdrawal of growth factors 
from the culture media (Figures 14 and 15). 
 
Figure 13. Average length of EC sprouts cultured in the presence of absence of SMCs in 
media containing VEGF and FGF-2 (10 ng/mL for each growth factor). 
 
Figure 14.  Average length of EC sprouts cultured in the presence of absence of 22,500 
SMCs in media containing VEGF and FGF-2 (10/ng/mL for each growth factor).  After 3 
days, the media was replaced with media that did not contain exogenous growth factors. 
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Figure 15.  Angiogenesis after VEGF, FGF-2 withdrawal in the presence and absence of 
SMCs (only ECs shown for simplification).  (Mag. 4x) 
In the presence of growth factors after 3 days, the ALS of ECs cultured in absence 
of SMCs was  133 +/- 17µm, and the ALS of ECs co-cultured in the presence of SMCs 
(22,000 SMCs/mL) was 128 +/- 13 µm (p = .70).  After withdrawal of growth factors, the 
ALS of ECs cultured in the absence of SMCs was 112 +/- 12 µm versus 211 +/- 16 in the 
presence of SMCs at Day 9 (p <.001).  Similarly at Day 13, ALS of ECs cultured in the 
absence of SMCs was 97 +/- 12 µm versus 222 +/- 26 in ECs cultured in the presence of 
SMCs (p < .001). 
At 13 Days, the average length of EC sprouts cultured in the absence of SMCs 
were 27.2 +/- 8.7% less than the length of EC sprouts at Day 3, while the average length 
of EC sprouts cultured in the presence of SMCs were 73.1 +/- 20.2% greater than the 
length of EC sprouts at Day 3 (p < 0.001). 
 No differences in the density of sprout network formation were found in groups 
which had been treated by exogenous growth factors. 
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SMCs Effects on Angiogenesis in Absence of Exogenous Growth Factors 
To determine the effects of SMCs in the absence of exogenous growth factors, 
angiogenesis from EC aggregates embedded within fibrin hydrogels that contained SMCs 
(400,000 cells/mL) were compared to angiogenesis from EC aggregates embedded in 
fibrin hydrogels which did not contain SMCs (Figures 16 and 17). The assays were 
cultured in angiogenesis assay media without exogenous growth factors for up to 17 days.  
By Day 3, the ALS of ECs cultured in the presence of SMCs was significantly greater 
than those cultured in the absence of SMCs (320 +/- 21 µm versus 187 +/- 16 µm; p < 
.005).  This significant difference persisted throughout the course of the entire 
experiment.  
 
Figure 16.  Quantification of angiogenesis in the presence and absence of SMCs (400,000 
SMCs/mL) in the absence of exogenous growth factors. 
Angiogenic networks in coculture continued to grow throughout the course of the 
experiment with the peak average length of co-cultured sprouts being 462 +/- 13 µm at 
Day 17.  The ALS of ECs cultured in the absence of SMCs at Day 17 was 202 +/- 27 µm, 
with a peak ALS of 233 +/- 8 µm at Day 13.  
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Figure 17.  Angiogenesis in the presence and absence of SMCs (400,000 SMCs/mL) in 
the absence of exogenous growth factors.  Only ECs shown for simplification (Mag. 4x). 
 Similarly, ECs in coculture formed more robust sprout networks, with the density 
of sprout formation (DSF) of co-cultured ECs being 42 +/- 8% versus 12 +/- 2% in ECs 
cultured in the absence of SMCs at Day 3 (p=.01).  At Day 17, the DSF of co-cultured 
ECs was 69 +/- 25% versus 7 +/- 3% in ECs not in co-culture (p= .02).  The peak DSF in 
co-cultured ECs was 76 +/- 7% at Day 13 versus 31 +/- 4% at Day 9 in ECs not in co-
culture. 
The Effects of SMCs on Angiogenesis with Direct SMC-EC Contact 
 The modulation the pro-angiogenic effects of SMCs by direct cell-cell contact 
was tested utilizing a direct cell contact angiogenesis assay modified from the methods of 
Korff and Augustin. 160  ECs seeded on the surface of an aggregate of SMCs were 
embedded in fibrin hydrogels and cellular invasion of each cell type was imaged and 
quantified over a 19 day period.  ECs and SMCs were found to co-invade into the 
extracellular matrix in close approximation to one another.(Figure 18)  At Day 7, the 
average length of EC sprouts was 205 +/- 32 µm and the average length of SMC invasion 
was 229 +/- 19 µm (p=.54).  Similarly, the ALS of EC and SMC sprouts did not 
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significantly differ at Day 13 (564 +/- 79 µm for SMCs versus 378 +/- 55 µm for ECs; 
p=.23).  At Day 19, SMC sprout lengths were significantly greater than EC sprout lengths 
(551 +/- 39 µm versus 327 +/- 58 µm; p=.03). 
 
Figure 18.  Invasion of ECs and SMCs into fibrin from co-culture aggregates.  Left) ECs 
(red) co-invade with SMCs (green) into fibrin hydrogel (Mag. 10x).   Right) Average 
length of EC and SMC invasion in co-culture aggregate model. 
To quantify the effects of SMC proliferation and invasion on EC invasion, ECs 
were seeded onto aggregates of SMCs that were either treated or untreated with MMC.   
MMC treatment had the effect of both inhibiting SMC proliferation and attenuating SMC 
matrix invasion to a maximal reduction of 40.0 +/- 2.2% of MMC untreated controls 
(p<.001), with significant reductions in SMC invasion at all time points (Figure 19). 
 ECs in co-culture with SMCs treated with MMC demonstrated significantly 
attenuated matrix invasion compared to ECs co-cultured with SMCs that were untreated 
with MMC (82 +/- 14 µm versus 205 +/- 32; p < .05) (Figure 20). 
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Figure 19.  Treatment of SMCs with MMC inhibits SMC (a) proliferation and (b) matrix 
invasion.  The effects of MMC treatment on SMC proliferation and matrix invasion in the 
absence of growth factors.  (a) SMC proliferation.  SMCs either treated or untreated with 
MMC were seeded onto 96 well plates and cultured in indicated media.  SMC 
proliferation was determined by quantifying tritiated thymidine incorporation.  Results 
are mean CPM +/- SEM from a representative experiment (n=4).   (b) SMCs either 
treated or untreated with MMC were embedded within fibrin hydrogels and matrix 
invasion was quantified.  Results represent the mean distance of invasion +/- SEM from a 
representative experiment (n=4-5).  * p < 0.05 vs. MMC untreated control. 
 
Figure 20.  Inhibiting SMC proliferation with MMC inhibits both SMC and EC matrix 
invasion into fibrin hydrogels in the co-culture aggregate model. 
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In the direct contact co-culture model, ECs that were co-cultured with SMCs 
demonstrated increased ALS compared to ECs that were cultured alone at all time points 
(Figures 21 and 22). At Day 7 the ALS of ECs cultured alone was 103 +-/ 31 µm versus 
205 +/- 32 µm of ECs in co-culture (p=.08).  At Day 19, ALS of ECs cultured alone was 
70 +/- 11 µm versus 327 +/- 58 of ECs in co-culture (p=.01). 
 
Figure 21.  EC sprouts in co-culture aggregate model in the presence and absence of 
SMCs.  Only EC sprouts are shown for simplification.(Mag. 4x) 
 
Figure 22.  Quantification of EC invasion in co-culture aggregate model.  ECs were 
cultured in the presence and absence of SMCs in the co-culture aggregate model and 
average length of sprouts (left) and density of sprout formation was quantified (right).   
 The DSF of co-cultured ECs was also significantly greater than that of ECs not in 
co-culture at Day 13 and Day 19 (p=.014 and .007, respectively). 
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Discussion 
 We have demonstrated a novel method for creating structures resembling 
capillaries in a 3-dimensional extracellular matrix incorporating both the endothelial cells 
and SMC-derived pericytes.   The presence of SMCs in the extracellular matrix did not 
alter the angiogenic response to angiogenic growth factors commonly used in tissue 
engineering to promote construct microvascularization.  In fact, the presence of SMCs in 
the extracellular matrix promoted the formation of microvascular networks in the absence 
of exogenous growth factors and promoted the persistence of the microvascular networks 
by blocking the regression of microvasculatures after growth factor removal over the 
length of the experiments carried out in these studies. 
 Several mechanisms for the promotion of capillary persistence by pericytes have 
been set forth.  One is that pericytes induce vessel stabilization by the production of 
survival factors.  This is supported by several lines of evidence: 1) Neonatal vessels 
which are resistant to oxygen-induced degeneration are associated with pericytes which 
express TGF-β1, which induces VEGFR-1 expression in ECs;162 2) 10T1/2 precursor 
cells produce VEGF upon TGF-β-mediated conversion to pericytes when in direct 
contact with ECs;163 3) Pericytes express Ang-1 in vitro and in vivo, a growth factor 
which is associated with basement membrane formation, EC quiescence and endothelial 
leak resistance, and capillary maturation ;164-167 and 4) Pericyte loss caused by PDGF 
inhibition in a rat model of retinopathy results in overexpression of VEGF/VEGFR2 in 
ganglion cells and other supporting cells.168 
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 Another is that pericytes significantly modulate the ECM remodeling capacity of 
ECs by directly influencing the local ECM composition.  Pericyte-conditioned media has 
been shown to limit both EC migration and branching in vitro by inducing the 
upregulation of PAI-1 in ECs.169  In addition, pericytes have been shown to produce 
TIMP-3 and induce TIMP-2 production in ECs, which specifically targets MT1-MMP, 
MT2-MMP and ADAM (a disintegrin and metalloprotease) proteinases, with the net 
effect of stabilizing microvasculatures by blocking both tube formation and 
regression.170-172  In addition, pericyte-mediated ECM deposition, specifically the 
deposition and synthesis of basement membrane, has also been proposed to promote EC 
quiescence and vessel stability.173-175  The importance of the basement membrane in 
vascular stability is demonstrated in laminin-8 knockout animals which demonstrate 
poorly developed microvasculature with defective basement membranes, noticeable 
deformities, and increased responsiveness to pro-angiogenic stimuli.176 
 In our studies, the presence of cell-cell contact, as demonstrated by experiments 
utilizing co-culture aggregates (co-culture model #2) composed of both ECs and SMCs 
was not sufficient in inhibiting the pro-angiogenic effects of SMCs during the time-
course of these studies.  We showed that even in the presence of direct SMC-EC contact, 
SMCs appeared to promote the invasion ECs into the fibrin matrix, with ECs appearing 
to co-invade in close approximation to SMCs.  Indeed, the inhibition of SMC 
proliferation and invasion alone inhibited both SMC and EC matrix invasion, suggesting 
that SMCs can direct the growth of ECs into the extracellular matrix.  This appears 
contradictory to the generally held belief that once incorporated into capillaries, pericytes 
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mediate the quiescence of ECs.  Direct contact via gap junctions, adhesion plaques, and 
adherens junctions, as well as indirect paracrine mechanisms between ECs and pericytes, 
allow for significant interactions which impact EC differentiation, migration, 
proliferation, and quiescence.122-125  In vitro, ECs in direct contact with pericytes have 
lower levels mitosis compared to ECs cultured alone, a process which may require Rho 
GTPase activity in pericytes.142,158,159  Similarly, ECs in close contact with SMCs in a 
spherical aggregate of SMCs in collagen gels demonstrated decreased responsiveness to 
VEGF (in the absence of Ang-2), increased inter-endothelial junctions, decreased PDGF-
B growth factor chain expression, and reduced apoptosis.160  ECs in co-culture with 
10T1/2 cells also display a significantly higher resistance to the permeability of a tracer 
molecule biotin-dextran which was associated with tightening of EC-EC tight junctions 
and with the localization of tight junction proteins plakoglobin, ZO-1, ZO-2, and 
occludin.161   
 The observations in our experiments, however, clearly show that SMCs in close 
contact with ECs can promote matrix invasion of ECs central to angiogenic processes.  
Thus, we conclude that the presence of cell-cell contact alone is not sufficient in 
promoting EC quiescence within the examined time course in this model.  Above 
discussed factors such as the components and structure of the extracellular matrix and 
culture media, EC and pericyte differentiation, the time course of pericyte-mediated 
effects (early vs. late in angiogenesis) and specific paracrine cytokines and growth factors 
released by either ECs or SMC all likely contribute to cell behavior in co-culture systems. 
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In addition, the observation that SMCs promote the early formation of microvascular 
networks within the first 3 days prior to significant SMC incorporation into capillaries in 
co-culture experiments with SMCs homogenously distributed around EC aggregates (co-
culture model #1) suggests that cell-cell contact is not required for the pro-angiogenic 
effects of SMCs.  The release of pro-angiogenic growth factors in this early period is a 
hypothetical explanation for this observed effect.  It is conceivable that the identity of the 
growth factors released by SMCs prior to significant incorporation into 
microvasculatures, differ from those released later in angiogenesis or after pericyte 
incorporation.  This could be an explanation for the apparent pro-angiogenic effects of 
SMCs early during our co-culture assays, and the apparent contradiction to the above 
described studies which demonstrated the stabilizing effects of pericyte-conditioned 
media.  
 Clinically, the simultaneous targeting of pericytes and ECs by pro- or anti-PDGF 
and VEGF therapy has been investigated in tissue engineering and oncologic research.  
Combination therapy has been shown in some studies to be more effective in disrupting 
tumor vascularity than either agent alone and, as such, combinatorial antitumor therapy is 
under investigation.147-150  It is unclear, however, if the apparent improved anti-
angiogenic effect observed in combination therapy is specifically attributable to PDGF 
blockade or to the broad non-specific effects of the receptor tyrosine kinase inhibitors 
used in most studies of combination therapy.  Recently, it was shown that adenoviral 
expression of soluble anti-PDGF-β receptor provided added inhibition of tumor growth 
and angiogenesis only when sub-optimal levels of VEGF blockade were present.151  
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Clearly, however, PDGF signaling does impact angiogenesis in vivo, as the 
spatiotemporal delivery of PDGF with VEGF has been shown to induce denser and more 
mature appearing vascular networks within tissue engineered constructs, which is in part 
associated with the recruitment of α-actin positive (indicative of pericytes) cells into the 
neovascular networks.152,153   
 The structures formed in our model resemble capillaries, with 2-3 ECs lining 
lumens within the matrix surrounded by several pericyte-like appearing structures derived 
from the SMCs in the matrix.  Histologically, the engineered microvasculatures appear to 
recapitulate the native structure of capillaries in vivo.  The functionality of these 
structures remains unclear.  Responsiveness to the angiogenic growth factors VEGF and 
FGF-2 suggest their viability and functionality.  Further studies studying nitric oxide 
pathways, prostacyclin synthesis, and other EC functional assays could be performed as 
potential future studies to determine the potential functionality of these capillaries in 
tissue engineered constructs. 
 In summary, we have demonstrated that SMCs promote both the formation and 
persistence of microvascular networks engineered in fibrin hydrogels, and that the 
presence of SMCs in the extracellular matrix does not alter the angiogenic response to 
exogenous growth factors commonly used in tissue engineering. 
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CHAPTER FIVE 
THE EFFECTS OF CO-CULTURE ON EC SIGNALING 
Introduction 
 The results of the previous Aim demonstrate that capillary networks formed in co-
culture with SMCs display both increased early formation and later persistence compared 
to ECs cultured in the absence of SMCs.  Our in vitro co-culture model of angiogenesis 
was devised both to test basic biologic processes within a 3-D microenvironment, and 
also to model angiogenic processes during vasa vasorum development in the wall of a 
fibrin-based tissue engineered blood vessel.  The goals of this Aim are 1) to test the 
hypothesis that the pro-angiogenic effects of SMCs are due to the release of SMC-
derived angiogens into the extracellular environment; and 2) to test the effects of these 
released products on EC signaling pathways involved in cell proliferation and survival. 
 The possibility that the demonstrated pro-angiogenic effects of SMCs in our 
fibrin-based angiogenesis model is accounted for, at least in part, by the release or 
deposition of products into the extracellular environment is supported by several 
observations in the literature.  Secreted VEGF or deposited ECM proteins such as 
fibronectin by SMCs and fibroblasts in vitro have been demonstrated to elicit angiogenic 
activities such as increased plasminogen activity, proliferation, motility, and cordlike 
structure formation in co-cultured ECs.99-104 
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The observed endothelin-1-mediated activation of EC mitogenesis by fibroblasts100 and 
the production of Ang-2 and VEGF in mesangial cells (renal pericytes) under hypoxic 
conditions 105 provide evidence that these paracrine interactions may be regulated by the 
local extracellular environment.  These data are consistent with observations that under 
hypoxic stimulation, VEGF-secreting perivascular cells appear to be the first vascular 
cells to invade the corpus luteum parenchyma during ovulatory angiogenesis.108   
It is likely that SMC-derived angiogens activate pathways mediated by the 
intracellular kinases ERK and Akt.  Capillary thickness as a result of cell proliferation 
and migration has been shown to be dependent on ERK 1/2 signaling via VEGF/VEGFR-
2 signaling, while PI3-K, an upstream regulator of Akt activity has been shown to be 
required for cell survival.183 We have chosen to quantify the extent of Akt and ERK 
phosphorylation in response to SMC-derived soluble factors as a proxy for cell signaling 
processes involved in cell survival and proliferation.  A detailed and extensive review of 
the intracellular signaling pathways involved in angiogenesis is well beyond the scope of 
this dissertation.  Reviews for further study are cited, and figures summarizing the basic 
PI3-K/Akt and ERK MAP Kinase pathways (Figures 23 and 24).6,74,184 This aim is 
intended to investigate these interactions in a 3-D fibrin-based extracellular environment. 
Methods 
Materials 
Chemicals, biological reagents, and experimental supplies were obtained as 
follows: collagenase (Invitrogen); human thrombin (American Red Cross; Rockville, 
MD); FGF-2, VEGF (R&D Biosciences); L-ascorbic acid, methylcellulose, fibrinogen,  
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Figure 23.  PI3-K/Akt pathway.6 
transferrin, insulin, anti–α-actin antibody and aprotinin, anti-VWF antibody , PKH-27, 
PKH67 (Sigma Chemical Co.; St. Louis, MO); tritiated thymidine (NEN Life Science 
Products; Boston, MA); methanol, trichloroacetic acid, acetic acid, and scintillation fluid 
(Fisher Scientific; Fair Lawn, NJ); bovine lung heparin (Upjohn; Kalamazoo, MI); 
Calcein AM (Molecular Probes, Eugene, Ore); 0.05% trypsin/EDTA, HBSS, M199, 
DMEM, L-nonessential amino acids, sodium pyruvate, penicillin, streptomycin, DMEM-
F12 (Gibco, Grand Island, NY); fetal bovine serum (FBS) (Hyclone, Logan, UT); 100-
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mm and 60mm Petri dishes (Fisher Scientific; Pittsburgh, PA); 24 well plates and tissue 
culture flasks, Costar Transwell polystyrene plates (Corning Costar Corp; Cambridge, 
MA); round bottom 96 well plates (Greiner Bio-one; North Carolina); 96 well 
polystyrene plastic plates (Beckton Dickinson; Lincoln Park, NJ). 
 
Figure 24.  The Ras/Raf/ERK 1/2 pathway.7   
Animal Care 
All animal procedures complied with The Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, Commission of Life 
Sciences, National Research Council, 1996) and The Principles of Laboratory Animal 
Care (National Institutes of Health publication no. 85-23, revised 1985) and were 
approved by our institutional IACUC. 
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Cell Isolation 
 SMCs and ECs were harvested from the canine carotid artery and jugular veins 
respectively per previously published protocols.179,180 Briefly, adult mongrel dogs were 
anesthetized with thiopental sodium, intubated, and ventilated. Anesthesia was 
maintained with nitrous oxide and methoxyflurane. Bilateral neck incisions were made.  
 For ECs, bilateral external jugular veins were removed, inverted, and processed 
per our previously reported protocol beginning with the veins being sequentially placed 
into 0.05% trypsin/EDTA 0.53 mmol/L and collagenase 100 U/mL at 37°C for 10 
minutes each. Next, the veins were discarded, and the trypsin and collagenase solutions 
were centrifuged. The subsequent pellets were resuspended in EC complete medium 
supplemented with FGF-1 (5 ng/mL), and the ECs were plated onto a fibronectin-coated 
(2.5 µg/cm2) T-25 culture flask that was incubated in a 37°C, 5% carbon dioxide 
chamber. The media was changed every 2 to 3 days, and confluent cells were passaged 
with trypsin-EDTA. EC identity was confirmed using immunofluorescent dual staining 
with anti-vWF and anti-α-actin antibodies. Only ECs exhibiting 95% positive vWF 
staining and 2% or less α-actin staining were used for the proliferation assays. EC were 
used within passages 1 to 5. 
 For SMCs, the carotid arteries were opened longitudinally, and the intima and 
adventitia were removed by sharp dissection. The medial layer was minced and placed 
into SMC growth media. Primary SMCs migrating from the explants were used in all 
experiments. SMC identity was confirmed by immunofluorescent staining with α-actin 
antibodies, and only cultures exhibiting 95% positive staining were used in the assays.  
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Individual carotid artery explants were used as the source of cells for assays no more than 
3 times.   
Methocel Preparation 
 Methylcellulose reagent (1.2 g) was autoclaved in a 250-mL beaker at 120°C for 
20 minutes. The autoclaved powder was dissolved in 50 mL of preheated (60°C) M199, 
stirred at 60°C for 20 minutes, and then 50 mL of M199 at room temperature was added. 
The solution was mixed for 2 hours at 4°C, centrifuged for 2 hours at 4,000 rpm, and the 
supernatant was collected after centrifugation. 182 
Multiple Aggregate Co-culture Assay 
 Multiple EC and SMC co-culture aggregates were embedded within the same 
hydrogel to test for directional invasion towards the other aggregates.  Co-culture 
aggregates were created as described in Aim #1 by suspending 2250 SMCs in an 
aggregating solution consisting of angiogenesis assay media and a 20% Methocel 
solution into each well of a round bottom 96-well plate.  The cells were incubated at 
37°C for 24 hours until smooth muscle cell aggregates formed.  After 24 hours, 350 ECs 
were added to each well and allowed to seed the surface of the SMC aggregates.  The 
aggregates of SMCs and ECs were incubated at 37°C for another 24 hours until co-
culture cell aggregates formed comprised of a smooth muscle cell core seeded by 
endothelial cells on the surface.  Multiple aggregates were embedded between two layers 
of fibrin gels in the wells of flat-bottom 96 well plates and cultured in angiogenesis assay 
media containing at 37°C.  After a period of time, SMCs and ECs invade from the central 
aggregate into the surrounding hydrogel.  Digital images were taken at a magnification of 
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4x in order to visually demonstrate the direction of radial invasion by co-culture sprouts.  
The experiment was performed 5 times, and representative images are reported. 
Conditioned Media Collection 
 To test if SMCs in culture produce soluble factors which affect EC angiogenic 
behavior, media conditioned by SMCs in culture was collected and used to stimulate EC 
proliferation, migration, angiogenic sprouting, and signaling responses (Figure 25). 
Proliferation and migration assays were chosen as they are generally considered requisite 
facets of angiogenic induction.  These data are meant to complement the results of the 3-
D angiogenesis assays, which hypothetically include proliferation, migration, matrix 
remodeling, and other aspects of angiogenesis and matrix invasion.  The presence of 
extracellular matrix can have the effects of altering cellular behavior.  For this reason, 
select experiments were carried out in which media conditioned by SMCs in standard 2-
D cell culture in 24-well polystyrene plates were collected in addition to media 
conditioned by SMCs embedded in a 3-D environment within fibrin hydrogels. 
To collect 2-D SMC-conditioned media, SMCs were cultured onto 24 well 
polystyrene plates (240,000 SMCs per well) in angiogenesis assay media.  After 72 hours 
the media was collected and the cells were discarded.  Angiogenesis assay media 
incubated in 24 well plates for 72 hours without cells served as the unconditioned media 
controls.  To collect 3-D SMC-fibrin-conditioned media, fibrin hydrogels with or without 
homogenously distributed SMCs as previously described (400,000 SMCs/mL of gel or 
240,000 cells when calculated by volume) were cultured in invasion assay media.  After 
72 hours of culture, the media in each group was collected and the hydrogels were  
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Figure 25.  Schematic depiction of conditioned media collection utilized as a stimulant 
for EC proliferation, migration, angiogenesis and signaling.  (Left) 2-D SMC-conditioned 
media.  SMCs are cultured on Petri dishes and the media is collected after 72 hours. 
(Bottom left) Unconditioned media is used as a control for experiments utilizing 2-D 
SMC-conditioned media.  (Right) 3-D Fibrin-SMC-conditioned media.  SMCs are 
cultured in fibrin hydrogels and the culture media is collected after 72 hours.  (Bottom 
right)  Media conditioned by acellular fibrin gels are used as controls for experiments 
utilizing 3-D SMC-Fibrin-conditioned media. 
discarded.  A bicinchoninic acid (BCA) protein assay was used to calculate the total 
protein content in each group.  This media was used to test for EC mitogenic, 
chemotactic, angiogenic, and signaling responses as described below.     
EC 2-D Proliferation Assay 
 Tritiated thymidine incorporation for evaluation of DNA synthesis was used to 
assay cell proliferation in 2-D culture as previously described.179  ECs were plated onto 
fibronectin-coated (2.5 µg/cm2) 96-well plates at an initial concentration of 10,000 cells 
per well with 200 µL of EC complete media and cultured for three days at 37 °C until 
they reached 80-90% confluence by estimation of cellular coverage over the area of the 
bottom of the well.   At that point, the medium was then removed; the cells were washed 
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with phosphate-buffered saline (PBS), and 200 µL of EC quiescent medium was placed 
in each test well to synchronize cells in G0 for 24 hours for ECs.  Cells were presumed to 
be viable if they did not wash away with washings, appeared morphologically normal, 
and proliferated in response to positive control wells stimulated by FBS.  The cells were 
then stimulated with unconditioned media, SMC-conditioned media, fibrin-conditioned 
media, or 3-D SMC-fibrin-conditioned media.  A BCA protein assay determined the total 
protein content in each conditioned media group, and the total volume was normalized to 
stimulate each group with equivalent amounts of total protein (total volume of 50 µL per 
well).  Fifty microliters of PBS was the negative control, and 50 µL of FBS (20% of total 
volume in the well) was the positive control. The next day, 1 µCi of tritiated thymidine 
was placed in each well for 24 hours. The wells were processed by removal of the media 
and washing with PBS. The cells were fixed in 100% methanol for 10 minutes, lysed 
with distilled water, and precipitated with 5% trichloroacetic acid. The cell lysates were 
washed with distilled water, and the DNA was solubilized with 0.3 mol/L sodium 
hydroxide. This solution was placed into 10 mL of scintillation fluid that contained 20 µL 
of acetic acid to avoid opacification of the scintillation fluid.  DNA synthesis was 
quantified by the amount of tritiated thymidine incorporated into cellular DNA over a 24 
hour incubation period and radioactivity in TCA precipitable material was measured 
using a scintillation counter units of counts per minute (CPM).  Each individual 
experiment was analyzed statistically with Student’s T-test with statistically consistent 
results.  The data represents the mean CPM +/- SEM from 3 independent experiments 
normalized to unconditioned or fibrin-conditioned controls.  
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EC 2-D Migration Assay 
 ECs were seeded on the inner membrane of a fibronectin-coated Costar Transwell 
polystyrene plate (8.0 µm pore size in the polycarbonate membrane) in angiogenesis 
assay media with 1% FBS.  After allowing the cells to attach for four hours, a test 
solution containing fibrin-conditioned media or 3-D SMC-fibrin-conditioned media was 
placed in the lower chamber in a total volume of 600 µL, normalized to total protein.  
After 6 hours of migration, the media in the upper and lower chambers were gently 
suctioned off and the non-migratory cells were scraped from the inner membrane with a 
cotton-tipped applicator. The remaining migratory cells were fluorescently labeled with 
Calcein AM.  Four quadrants of the membrane were visualized under FITC at a 
magnification of 4x and fluorescent cells were counted and averaged for each well.  Each 
group was tested in replicates of four and the experiment was performed twice.  Mean 
results from each individual well are presented as the mean migratory cells per visual 
field +/- SEM (n=8). 
Angiogenesis Assay 
 ECs were aggregated and embedded within fibrin hydrogels as previously 
described in Aim#1.  They were cultured in media conditioned either by SMC-fibrin gels 
or by acellular fibrin gels.  The average lengths of sprouts were quantified as described in 
Aim #1.  The experiment was performed in replicates of four and the experiment was 
duplicated.  The pooled data from the two independent experiments are presented as 
mean length of sprouts +/- SEM (n= 8). 
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Signaling Assays 
 ECs were plated on fibronectin-coated (2.5 µg/cm2) polystyrene 30mm Petri 
dishes.  After a 4 hour quiescence period in serum free M199, the cells were stimulated 
with either 2-D SMC or 3-D SMC-fibrin-conditioned media, or 2-D unconditioned or 3-
D fibrin-conditioned media for 20 minutes.  Protein content was determined in each of 
the conditioned or unconditioned medias prior to use as stimulants.  Volumes were 
adjusted in order to stimulate with equal amounts of protein (from serum, SMC released 
products, etc.) in each conditioned and unconditioned media pair.  After 20 minutes, the 
cells were lysed with buffer, scraped, and centrifuged for 20 minutes at 10,000 g.  The 
supernatant was collected and a BCA protein assay was performed in order to determine 
the protein content in each group.  Western blot analysis was used to determine the 
amount of total ERK, phosphorylated ERK, total Akt, and phosphorylated Akt.  Blots 
were probed with anti-active MAPK (1:5000), anti-total ERK 2(1:3300), anti-pAkt (Ser 
471; 1:1000), and anti-pan Akt (1:1000) overnight at 4°C.  The blots were washed and 
probed by HRP-conjugated IgG (1:5000) for 2 hours, washed, and exposed on ECL 
hyperfilm.  Western blots were quantified by densitometry (Un-Scan-it Gel 6.1, Silk 
Scientific, Inc; Orem, Utah), and phosphorylated ERK and Akt was normalized to their 
respective total protein amounts.  The experiment was performed 3 times.  The data are 
the pooled means of each independent experiment +/- SEM. Table 1 summarizes the 
conditioned media tested for each assay. 
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Table 1.  Summary of Conditioned Media and Controls Tested in EC Assays in Aim 2. 
 
2-D SMC-
Conditioned 
media 
Unconditioned 
media 
(control) 
3-D SMC-
Fibrin-
conditioned 
media 
3-D Fibrin-
conditioned 
media 
(control) 
     
EC Proliferation X X X X 
EC Migration   X X 
EC Angiogenesis   X X 
EC Signaling X X X X 
     
 
Results 
Directional Invasion from Multiple Co-Culture Aggregates 
 Multiple co-culture aggregates were embedded within individual fibrin hydrogels 
(Figure 26). Digital images were taken which included the embedded aggregates and the 
sprouts radiating from the aggregates.  Sprouts radiating from the co-culture aggregates 
qualitatively demonstrated directional invasion towards other sprouts within the same 
hydrogel.  Single aggregates demonstrated random, non-directional sprouting by visual 
estimation.  Assays were performed 5 times with representative images demonstrated in 
the figure. 
 
Figure 26.  Directional invasion for co-culture aggregates.  (Left) Individual SMC/EC co-
culture pellets demonstrate random invasion into hydrogel. (Right panels) Co-culture 
pellets demonstrate directional invasion towards one another in hydrogels. 
75 
 
 
Proliferation Assay 
 Media conditioned by SMCs in either 2-D culture or in 3-D fibrin culture was 
used to stimulate quiescent ECs cultured in a monolayer on 96 well plates (Figure 27). 
ECs stimulated with media conditioned by SMCs in 2-D culture demonstrated thymidine 
incorporation that was 30.7% greater than ECs stimulated by media unconditioned by 
SMCs (100 +/- 5.0% vs. 131 +/- 15.0%; p=.066).  ECs stimulated by media conditioned 
by SMCs cultured in 3-D fibrin hydrogels demonstrated thymidine incorporation that was 
35.9% greater than ECs stimulated by media conditioned by acellular fibrin hydrogels 
(100 +/- 4.0 vs. 136 +/- 4.2%; p < .001).  
 
Figure 27.  SMC-conditioned media induces EC proliferation. EC were cultured in the 
presence SMC-conditioned or unconditioned media and EC mitogenicity was determined 
by tritiated thymidine incorporation.(Left) ECs stimulated by media conditioned by 
SMCs in 2-D culture.  (Right) ECs stimulated by media conditioned by SMCs in 3-D 
culture. 
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Migration assay 
 EC chemotaxis towards media conditioned by SMCs in 3-D fibrin hydrogel 
culture was tested with a modified Boyden chamber assay (Figure 28). Migratory cells in 
groups migrating towards SMC-conditioned media were 4.7–fold greater than control 
groups migrating toward media conditioned by acellular fibrin hydrogels (3.6 +/- 1.0 vs. 
17.0 +/- 1.9 cells/visual field; p < .001). 
 
Figure 28.  SMC-conditioned media induces EC migration.  (Top panels) Migratory cells 
in a representative quadrant (Mag. 4x) in a modified Boyden chamber assay in response 
to unconditioned (left) and SMC-conditioned (right) media. 
Angiogenesis assay 
 EC angiogenesis in response to media conditioned by SMCs in 3-D fibrin 
hydrogel culture was tested.(Figure 29)  The average length of sprouts in groups cultured 
in 3-D SMC-fibrin-conditioned media was 488% of controls containing media 
conditioned by acellular fibrin hydrogels (63.1 +/- 7.1 vs. 12.9 +/- 7.5 µm; p < .01). 
Signaling 
 Media conditioned by SMCs in either 2-D culture or in 3-D fibrin culture was 
used to stimulate quiescent ECs cultured in 30 mm polystyrene Petri dishes.  The 
phosphorylation of ERK and Akt was tested with Western blot analysis (Figures 30 and  
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Figure 29.  SMC-conditioned media induces angiogenesis.  EC cultured in unconditioned 
media (top left) vs. SMC-conditioned media (top right).  Bottom) Average length of EC 
sprouts cultured in SMC-conditioned vs. unconditioned media. 
31)  pERK/total ERK levels in ECs stimulated by 2-D SMC-conditioned media was 7.7X 
greater than controls  (771.1 +/- 182% vs. 100.0 +/- 12.6%; p=0.02) and 3.2X greater 
than controls in ECs stimulated with 3-D SMC-Fibrin-conditioned media (324.2 +/- 
60.8% vs. 100.0 +/- 17.0%; p= .02).  pAkt/total Akt levels in ECs stimulated by 2-D 
SMC-conditioned media was significantly less than controls (100.0 +/- 14.2% vs. 27.3 
+/- 10.7%; p=0.006).  This was also seen in ECs stimulated with 3-D SMC-Fibrin-
conditioned media (100.0 +/-34.3% vs. 26.6 +/- 4.4%; p=0.03).  
In the absence of fetal bovine serum, no Akt phosphorylation was demonstrated in 
control unconditioned media groups (Figure 32). ERK phosphorylation was unaffected 
(not shown). 
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Figure 30.  Levels of phosphorylated endothelial cell ERK after stimulation with SMC-
conditioned or unconditioned media.  Cell lysates were collected and pERK levels were 
quantified by Western blot analysis. 
 
Figure 31.  Levels of phosphorylated endothelial cell Akt after stimulation with SMC-
conditioned or unconditioned media.  Cell lysates were collected and pAkt levels were 
quantified by Western blot analysis. 
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Figure 32.  Levels of phosphorylated Akt in ECs after stimulation with fetal bovine 
serum.  ECs were plated on 30mm Petri dishes and stimulated by angiogenesis assay 
media with or without serum for 20 minutes.  Cell lysates were collected and pAkt levels 
were assayed with Western blot analysis. 
Discussion 
 The results of this Aim provide a mechanistic explanation for the pro-angiogenic 
effects of SMCs in our co-culture model system.  SMCs cultured both in conventional 2-
D culture and in 3-D fibrin hydrogels release products into the extracellular environment 
that promote angiogenic processes in ECs.  This is supported by the observation that 
sprouts from multiple SMC/EC co-culture aggregates placed within the same fibrin 
hydrogel demonstrate preferential invasion towards sprouts from adjacent co-culture 
aggregates.  We hypothesize that this is at least partly a function of the release of 
chemotactic agents that are released and deposited as a gradient onto the extracellular 
matrix.  In addition, remodeling of the ECM by proteases from the SMCs, ECs, or both 
may also create microscopic channels in the hydrogel that provide a path of least 
resistance for sprouts within the vicinity.  The results of the previous Aim, which 
demonstrated that the inhibition of SMC matrix invasion and proliferation inhibited both 
SMC and EC matrix invasion, provide support for this mechanistic hypothesis. 
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 It is clear, however, that the release of pro-angiogenic products into the 
extracellular environment is a key component to the pro-angiogenic effects of SMCs.  
ECs cultured in SMC-conditioned media (but in the absence of SMCs) demonstrate 
increased proliferation, migration and angiogenesis compared to ECs cultured in media 
unconditioned by SMCs.  We have not identified these products.  However, we 
hypothesize that these include growth factors and other cytokines such as VEGF, 
angiopoeitin, endothelin-1, and others, which are known to be released by perivascular 
cells such as SMCs.185-187 100  
 In addition, the degradation of the fibrin products by SMC-derived proteases may 
release fibrin degradation products into the media, which are known to affect 
angiogenesis.188   In fact, the modulation of the ECM by pericytes is thought to be a 
critical component for the function of pericytes during angiogenesis, most commonly 
studied in the context of the later stabilization of microvasculatures.  Pericyte-conditioned 
media has been shown to limit both EC migration and branching in vitro by inducing the 
upregulation of protease inhibitors in ECs.169  In addition, pericytes have been shown to 
produce various tissue inhibitors of metalloproteinases (TIMP) and induce specific TIMP 
production in ECs, which have been shown to decrease the angiogenic potential of 
ECs.170-172  In addition, pericyte-mediated ECM deposition, specifically the synthesis and 
deposition of basement membrane, has also been proposed to promote EC quiescence and 
vessel stability.173-175  The results of these studies demonstrate that perivascular cells such 
as SMCs can not only provide the stabilizing stimuli, but also have functions which 
promote the early formation of angiogenic networks.   
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 In our studies, media conditioned by SMCs in 2-D culture absent of fibrin induced 
similar EC cell signaling responses to those seen in ECs stimulated by media conditioned 
by SMCs in 3-D fibrin culture.  This suggests that the extracellular matrix is unnecessary 
for the pro-angiogenic effect of SMCs in our model.  Similar results in cell proliferation 
also support this conclusion.  This does not, however, discount the importance of the 
ECM in modifying the cell-cell interactions either by modifying the identity of the 
angiogenic products released by SMCs, affecting the functionality of those products, or 
modulating the specific EC responses to those products. 189  The effects of the fibrin 
ECM are not specifically investigated in these studies.  However, these are an important 
component to the cell-cell and cell-matrix  interactions present during angiogenesis and 
are worthy of further inquiry. 
 We also have demonstrated that the stimulation of ECs with media conditioned by 
SMCs cultured in both 2-D and 3D culture environments affects cell signaling responses 
involved in cell proliferation and survival.  The activation of the intracellular signaling 
kinase ERK 1/2 is consistent with the demonstrated pro-mitogenic effects of SMC-
conditioned media seen at the cellular level.  This suggests that the pro-angiogenic 
response of ECs to SMC-conditioned media is likely in part due to either growth factors 
directly secreted by SMCs or to induced autocrine growth factor effects in ECs.   
 Results of the previous Aim demonstrated that the presence of SMCs induced 
both the early formation of angiogenic networks and the later persistence of the networks 
in comparison to ECs cultured alone.  This appears to be in contrast to the observed 
suppression of basal levels of EC Akt by SMC-conditioned media, considering the 
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known pro-survival effects of the PI3-K/Akt pathway.190,191  Serum factors in 
experimental media was required for the activation of Akt.  The possibility that these 
serum factors were present in lower concentrations in SMC-conditioned media 
(hypothetically, cultured SMCs could have utilized these factors during the conditioning 
culture period) was controlled for by normalizing the conditioned and control media to 
total protein levels prior to stimulating ECs.   
 Explanations for these are speculative at this point.  One hypothesis is that the 
identity of the secreted growth factors in our system, and/or the EC signaling responses to 
these growth factors, change over time in culture.  This could be due to potential 
phenotypic changes in SMCs and/or ECs induced by direct cell-cell contact or close 
cellular approximation after incorporation of SMCs as capillary pericytes.141,157,192,193  
PDGF, known to be secreted by ECs, and crucial in the recruitment of pericytes to 
neocapillaries, has been shown to increase expression of pro-angiogenic mediators 
including angiopoeitin-1 (Ang-1) in SMCs. 194  Ang-1 acts as an EC Tie-2 receptor 
agonist, causing rapid receptor transphosphorylation, leading to subsequent downstream 
activation of the protein kinase B/Akt/FKHR (FOX01) pathway to promote EC survival, 
a potential mechanism of pericyte-induced neocapillary stability.195,196  In these studies, 
SMC-conditioned media was collected after 72 hours of culture without any reciprocal 
interaction with ECs.  Therefore, it is possible that the signaling events that are being 
tested in these experiments more precisely model the early events in our co-culture 
system described in Aim #1, prior to the events which lead to the activation of EC pro-
survival and stability pathways.  Indeed, the deactivation of Akt, may reflect processes 
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early in angiogenesis which destabilize the endothelium, and thus promote a more 
synthetic and dynamic EC phenotype required for initial capillary formation.  
In summary, we have demonstrated that SMCs promote the early formation and 
later persistence of capillary networks engineered in fibrin hydrogels (Figure 33). Our 
fibrin-based co-culture system results in capillary networks comprised of SMCs acting as 
pericytes around EC lined tubules in a 3-D environment.  SMCs release angiogens that 
promote EC proliferation, migration, and angiogenesis.  These angiogens activate ERK 
1/2 while deactivating basal levels of Akt in ECs.  Alternatively, SMCs may release 
products in the extracellular environment that induce the release of angiogens from ECs 
which act in autocrine fashion to promote angiogenesis. 
 
Figure 33.  Summary of results of Aims 1 and 2. 
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CHAPTER SIX 
THE ROLE OF NOTCH IN MEDIATING SMC/EC INTERACTIONS 
Introduction 
 In the previous two Aims, we have demonstrated that SMCs promote angiogenic 
network formation and persistence in fibrin hydrogels, at least in part due to the release of 
products that are mitogenic, chemotactic, and angiogenic for ECs.  These products also 
activate ERK 1/2 by inducing its phosphorylation, while deactivating Akt by affecting its 
dephosphorylation.  The current Aim intends to identify the role of Notch signaling in 
mediating these molecular and cellular events. 
 Signaling through Notch, a cell membrane receptor, is an evolutionarily 
conserved pathway which impacts cell fate and differentiation determination (Figure 
34).197  Notch is a known mediator of EC-EC cell signaling during angiogenesis which 
affects EC quiescence, apoptosis, differentiation, and branching behavior.198,199  Notch 
receptors and their Delta-like-ligand 4 (Dll4) appear to be central components in 
restricting the formation of tip cells in response to VEGF within angiogenic sprouts, 
which limits the branching and sprouting patterns of angiogenic networks200 and limits 
tube diameter by inhibiting EC proliferation.201  Consistent with these results, the Notch 
intracellular domain (NICD), which is the cleaved active domain of the Notch receptor, 
has been shown to decrease VEGF-induced ERK 1/2 phosphorylation in ECs, and Notch 
has been shown to activate expression of VEGFR-3 and the anti-
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apoptotic protein Bcl-2.202  Blockade of delta-like ligand 4 in tumor-associated ECs leads 
to the increased vascularity and branching of tumors, although these microvasculatures 
demonstrate poor function and are associated with decreased tumor growth.203,204 
  
Figure 34.  Ligand-mediated Notch signaling.5    
 In addition to its role in modulating EC-EC cell-cell signaling, several studies 
have suggested the role of Notch in EC and pericyte interactions during angiogenesis:  1) 
SMC Notch mediates post-ischemic neovascular patterning, morphology and 
collateralization in the cerebral arterial circulation after carotid artery ligation;205 2) 
Disruptions in Notch signaling are associated with dysfunction in pericyte coverage in 
angiogenic networks;202 3) Notch-3 mediates PDGF-β expression in SMCs and the SMC 
response to PDGF-BB;206 4) Notch is required for differential gene expression seen in 
fibroblast/EC co-culture systems;207 and 5) Pericyte Notch-3 is required for EC-induced 
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phenotypic differentiation of pericytes, and mediates subsequent autoregulatory 
upregulation of pericyte Notch-3 and Jagged-1 expression.208  These observations suggest 
that Notch signaling mediates the recruitment of pericytes to neovasculatures, as well as 
their subsequent genetic expression and phenotype, including the induced expression of 
pericyte Notch ligands.  However, while Notch signaling within ECs is known to 
modulate their angiogenic behavior, and while the active intracellular cleavage domain, 
NICD, can directly affect intracellular phosphorylation events, the modulation of pericyte 
effects on ECs by Notch is unknown.   
This Aim will investigate the role of EC notch signaling on the pro-angiogenic 
effects of SMCs on ECs in our fibrin-based co-culture model system.   
Materials and Methods 
Materials 
 Chemicals, biological reagents, and experimental supplies were obtained as 
follows: collagenase (Invitrogen); human thrombin (American Red Cross; Rockville, 
MD); FGF-2, VEGF (R&D Biosciences); DAPT, methylcellulose, fibrinogen, insulin, 
anti–α-actin antibody and aprotinin, Anti-VWF antibody (Sigma Chemical Co.; St. Louis, 
MO); bovine lung heparin (Upjohn; Kalamazoo, MI); 0.05% trypsin/EDTA, HBSS, 
M199, DMEM, L-nonessential amino acids, sodium pyruvate, penicillin, streptomycin, 
DMEM-F12 (Gibco, Grand Island, NY); fetal bovine serum (FBS) (Hyclone, Logan, 
UY); 100-mm and 60mm Petri dishes (Fisher Scientific; Pittsburgh, PA); 24 well plates 
and tissue culture flasks, Costar Transwell polystyrene plate (Corning Costar Corp; 
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Cambridge, MA); round bottom 96 well plates (Greiner Bio-one; North Carolina); 96-
well polystyrene plastic plates (Beckton Dickinson; Lincoln Park, NJ).  
Animal Care 
 All animal procedures complied with The Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, Commission of Life 
Sciences, National Research Council, 1996) and The Principles of Laboratory Animal 
Care (National Institutes of Health publication no. 85-23, revised 1985) and were 
approved by our institutional IACUC. 
Cell Isolation 
 SMCs and ECs were harvested from the canine carotid artery and jugular veins, 
respectively per previously published protocols.179,180 Briefly, adult mongrel dogs were 
anesthetized with thiopental sodium, intubated, and ventilated. Anesthesia was 
maintained with nitrous oxide and methoxyflurane. Bilateral neck incisions were made.  
 For ECs, bilateral external jugular veins were removed, inverted, and processed 
per our previously reported protocol beginning with the veins being sequentially placed 
into 0.05% trypsin/EDTA 0.53 mmol/L and collagenase 100 U/mL at 37°C for 10 
minutes each. Next, the veins were discarded, and the trypsin and collagenase solutions 
were centrifuged. The subsequent pellets were resuspended in EC complete medium 
supplemented with FGF-1 (5 ng/mL), and the EC were plated onto a fibronectin-coated 
(2.5 µg/cm2) T-25 culture flask that was incubated in a 37°C, 5% carbon dioxide 
chamber. The media was changed every 2 to 3 days, and confluent cells were passaged 
with trypsin-EDTA. EC identity was confirmed using immunofluorescent dual staining 
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with anti-vWF and anti-α-actin antibodies. Only EC exhibiting 95% positive vWF 
staining and 2% or less α-actin staining were used for the proliferation assays. EC were 
used within passages 1 to 5. 
 For SMCs, the carotid arteries were opened longitudinally, and the intima and 
adventitia were removed by sharp dissection. The medial layer was minced and placed 
into SMC growth media. Primary SMCs migrating from the explants were used in all 
experiments. SMC identity was confirmed by immunofluorescent staining with α-actin 
antibodies, and only cultures exhibiting 95% positive staining were used in the assays.  
Individual carotid artery explants were used as the source of cells for assays no more than 
3 times.  
Methocel Preparation 
 Methylcellulose reagent (1.2 g) was autoclaved in a 250-mL beaker at 120°C for 
20 minutes. The autoclaved powder was dissolved in 50 mL of preheated (60°C) M199, 
stirred at 60°C for 20 minutes, and then 50 mL of M199 at room temperature was added. 
The solution was mixed for 2 hours at 4°C, centrifuged for 2 hours at 4,000 rpm, and the 
supernatant was collected after centrifugation. 
Conditioned Media Collection 
 To collect SMC conditioned media, 240,000 SMCs per well were cultured in 24 
well plates in angiogenesis assay media as previously described in Aim #2.  After 72 
hours of culture, the media was collected.  Angiogenesis assay media incubated in the 
absence of SMCs for 72 hours serve as the unconditioned media controls.  A BCA 
protein assay was used to calculate the total protein content in each group and 
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experimental and control groups in experiments were normalized to total protein.  This 
media was used to test for EC angiogenic and signaling responses as described below.   
Notch Inhibition and Signaling 
 In experiments that tested the effects of Notch inhibition on EC signaling 
pathways, ECs were plated on fibronectin-coated (2.5 µg/cm2) 30 mm polystyrene Petri 
dishes.  After a 3 hour quiescence period in serum free M199, DAPT (25µM) was added 
to the media and cells were incubated for an additional hour.   
Effects of Notch Inhibition on Growth Factor Induced Signaling 
 After the period of quiescence and DAPT pretreatment, the media was removed, 
and the cells were stimulated with angiogenesis assay media with 2.5% FBS containing 
VEGF + FGF-2 (10ng/mL for each growth factor in combination) and DAPT (25µM) for 
either 20 minutes or 48 hours in fresh serum free media containing 25µM DAPT.  In 
experiments carried out for 48 hours, media, growth factors and DAPT were replenished 
after the first 24 hours.  Controls in all DAPT experiments were pretreated with the 
DMSO carrier in equimolar amounts.    
Effects of Notch Inhibition on SMC-Conditioned Media Induced Signaling 
 In experiments testing SMC-conditioned media, after the period of quiescence 
and DAPT pretreatment, the media was removed, and 2-D SMC-conditioned or 
unconditioned media was added with or without DAPT to stimulate ECs for 20 minutes.  
Controls in all DAPT experiments were pretreated with the DMSO carrier in equimolar 
amounts.   Protein content was determined in each of the conditioned or unconditioned 
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media prior to use as stimulants.  Volumes were adjusted in order to stimulate with equal 
amounts of protein in each conditioned and unconditioned media pair.   
Western Blots 
 Cells were lysed with buffer, scraped, and centrifuged for 20 minutes at 10,000 g.  
The supernatants were collected and a BCA protein assay was performed in order to 
determine the protein content in each group.  Western blot analysis was used to determine 
the amount of total ERK, phosphorylated ERK, total Akt, and phosphorylated Akt.  Blots 
were probed with anti-active MAPK (1:5000), anti-total ERK 2(1:3300), anti-pAkt (Ser 
471; 1:1000), anti-pan Akt (1:1000), or anti-GAPDH (1:1000) overnight at 4°C.  The 
blots were then washed and probed by HRP-conjugated IgG (1:5000) for 2 hours, 
washed, and exposed on ECL hyperfilm.  Western blots were quantified by densitometry 
(Un-Scan-it Gel 6.1, Silk Scientific, Inc; Orem, Utah), and phosphorylated ERK and Akt 
was normalized to their respective total protein amounts.  Experiments were performed 3-
5 times, and the pooled means +/- SEM from each independent experiment is presented.  
For experiments testing the effects of DAPT pretreatment on EC signaling responses to 
VEGF + FGF-2 the results were normalized to ECs unstimulated by growth factors and 
untreated with DAPT.  In experiments testing the effects of DAPT pretreatment on EC 
signaling responses to SMC-conditioned media, the results were normalized to the mean 
densitometric measurements of ECs stimulated by SMC-conditioned media untreated 
with DAPT.   
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Identifying Notch Receptor and Ligand 
 ECs or SMCs were plated on fibronectin-coated plates in angiogenesis assay 
media with 2.5% FBS and treated with VEGF and FGF-2 in combination (10ng/mL for 
each growth factor) for 48 hours.  The growth factors and media were replenished after 
48 hours.  The presence of Notch 1, 2, 3, and 4 as well as Jagged-1 and Dll-4 was tested 
by Western blot analysis as previously described.  Primary antibodies (Santa Cruz) were 
added at a dilution of 1:250 and incubated overnight at 4˚C.  The blots were washed and 
probed by HRP-conjugated -anti rabbit IgG (1:5000) for 2 hours, washed, and exposed on 
ECL hyperfilm.   
Notch Inhibition and Angiogenesis 
 ECs were aggregated as previously described and embedded in fibrin hydrogels 
which contained 25µM of DAPT or an equal volume of DMSO.  The assays were then 
cultured in 2-D SMC-conditioned media or unconditioned media.  To test the effects of 
Notch signaling, either 25µM of DAPT or an equal volume of DMSO (DAPT carrier) 
was added to the culture media.  The media was changed and the DAPT or DMSO was 
replenished daily.  After 72 hours, the assays were digitally imaged and angiogenesis was 
quantified by calculating the average length of sprouts as described in Aim #1.  The 
experiment was performed in duplicate and the pooled results are presented as mean 
length of sprouts +/- SEM (n=9-10).   
Eosin Uptake 
 In order to approximate the kinetics of uptake of DAPT into fibrin hydrogels, the 
fluorophore eosin (620 Da) was utilized due to its similar molecular weight to DAPT.  
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Acellular fibrin hydrogels were created in 96 well plates.  Angiogenesis assay media 
containing eosin (1:100) was added to each well.  Gels and media were collected at time 
0 and then at 1, 2, 4, 24, and 48 hours of incubation with eosin containing media.  The 
fluorescence of both the gel and media component was measured with a fluorescence 
plate reader (Perkin Elmer, Waltham, MA) at 560 nm.  A group of gels were also 
analyzed further by counting the fluorescence of gel  surfaces and deep layers separately 
in order to demonstrate penetration of eosin into the gel.  The predicted amount of 
fluorescence in the gel and media components based on volume distribution was 
calculated by multiplying the total fluorescence in the well (fluorescence in media + 
fluorescence in gel) by the % of the volume occupied by the gel or the media, 
respectively.  The data was normalized to this predicted amount.  Positive controls were 
wells that contained eosin-containing media without gels that was collected after periods 
of incubations at time points described above.  The experiment was duplicated and a 
representative set of results are presented as mean fluorescence +/- SEM (n=4-5). Table 2 
summarizes the groups in the major above described experiments. 
Table 2.  Summary of Experiments in Aim 3. 
 
VEGF + 
FGF-2 
VEGF + 
FGF-2 + 
DAPT 
Unconditi
oned 
Media 
2-D 
SMC-
condition
ed Media 
2-D 
SMC-
condition
ed Media 
+ DAPT 
      
EC signaling X X X X X 
Notch Receptor/Ligand X     
Angiogenesis   X X X 
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Results 
Effects of Notch Inhibition on EC Akt and ERK 1/2  
Phosphorylation in Response to Growth Factors: 
 ECs stimulated by VEGF and FGF-2 in combination (10ng/mL for each growth 
factor) demonstrated a 2.25-fold increase in phosphorylated Akt compared with 
unstimulated controls (225 +/- 43.2% vs. 100.0 +/- 36.1%; p =.04; Figure 35).  Increases 
in phosphorylated Akt in growth factor stimulated ECs pretreated with DAPT was 
significantly higher compared with growth factor stimulated ECs that were not pre-
treated with DAPT (373.7 +/- 51.5% vs. 225 +/- 43.2% of unstimulated, non-DAPT 
treated controls; p< .05).  DAPT pre-treatment had no effect on levels of phosphorylated 
Akt in ECs that were not stimulated with growth factors. 
 
Figure 35.  ECs treated with DAPT and stimulated with growth factors for 20 minutes 
demonstrate increased levels of phosphorylated Akt compared to DAPT untreated cells 
stimulated with growth factors. *p < .05. 
Levels of phosphorylated ERK was 12.3-fold higher in ECs that were stimulated 
with growth factors compared with ECs that were unstimulated with growth factors 
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(1230.0 +/- 112% vs. 100.0 +/- 36.8%; p < .001; Figure 36).  The pretreatment of ECs 
with DAPT had no effect on the levels of phosphoryled ERK in response to growth 
factors compared with cells that were not stimulated with growth factors (p=.46).  DAPT 
pretreatment had no effect on levels of phosphorylated ERK in cells that were not 
stimulated with growth factors. 
 
Figure 36.  Notch inhibition and growth factor induced ERK1/2 phosphorylation in ECs.  
Notch inhibition with DAPT does not affect levels of phosphorylated ERK 1/2 in growth 
factor stimulated ECs (20 minutes of stimulation) treated with DAPT compared to DAPT 
untreated cells.  
ECs were stimulated with VEGF + FGF-2 in the presence and absence of DAPT 
for 48 continuous hours to determine if protein levels were affected by growth factors 
(Figures 37 and 38).  After 48 hours, levels of phosphorylated Akt did not differ in 
growth factor-treated groups in the presence or absence of DAPT compared with 
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unstimulated cells untreated with DAPT (p= 0. 72).  Total Akt also did not differ among 
any of the groups (p= 0.46; Figure 37).
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After 48 hours of continuous growth factor stimulation, levels of phosphorylated 
ERK were not significantly increased compared with unstimulated ECs in DAPT 
untreated cells(p= .19; Figure 38).  DAPT pretreatment did not affect levels of 
phosphorylated ERK in growth factor-stimulated cells compared with unstimulated ECs 
that were untreated with DAPT.  Total levels of ERK were not significantly altered by 
growth factor stimulation or DAPT treatment (p= 0.75). 
Notch Ligands and Receptors on ECs and SMCs 
 Notch 1, 3 and 4 was detectable on ECs and Notch 1 and 3 was detectable on 
SMCs by Western blot analysis.  This was consistent in cells that were either stimulated 
or unstimulated with VEGF + FGF-2 for 48 hours.  Dll-4 was detectable in both cell 
types in the presence and absence of growth factors in ECs and SMCs.  Neither Notch-2 
nor Jagged-1 was detectable in either cell type both in the presence and absence of 
growth factors (Figures 39 and 40). 
Effect of Notch Inhibition on EC Signaling Responses 
to SMC-Derived Soluble Factors  
Phosphorylated Akt levels in ECs stimulated by media unconditioned by SMCs in 
2-D culture were significantly greater than cells which were stimulated by conditioned 
media (366.9 +/- 52.1% vs. 100.0 +/- 39.3% for unconditioned vs. conditioned media 
groups, respectively; p< 0.01; Figure 41).  pAkt levels in DAPT-pretreated ECs 
stimulated with SMC-conditioned media was 5.6X greater than in non-pretreated ECs 
stimulated with SMC-conditioned media (558.1 +/- 104.4% vs. 100.0 +/- 39.3%; p= 
.003), not significantly different than ECs untreated with DAPT and stimulated with  
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Figure 39.  Dll-4 expression on ECs and SMCs in the presence and absence of VEGF + 
FGF-2 (10ng/mL for each growth factor). 
 
Figure 40.  Notch receptors on ECs and SMCs in the presence and absence of VEGF + 
FGF-2 (10ng/mL for each growth factor). 
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Figure 41.  Notch inhibition on levels of phosphorylated Akt in ECs stimulated with 
SMC derived soluble factors.  ECs were plated on Petri dishes and stimulated with SMC-
conditioned media either in the presence or absence of DAPT for 20 minutes. 
unconditioned media (558.1 +/- 104.4% vs. 366.9 +/- 52.1% for DAPT/SMC-conditioned 
vs. no DAPT/unconditioned groups, respectively; p= .18). 
Phosphorylated ERK 1/2 levels in ECs stimulated by media conditioned by SMCs 
in 2-D culture was significantly greater than ERK 1/2 levels in ECs stimulated by 
unconditioned culture media (12.9 +/- 1.6% vs. 100.0 +/- 23.6% for unconditioned vs. 
conditioned groups, respectively, p=0.02; Figure 42).  DAPT treatment did not affect 
levels of phosphorylated ERK in response to SMC-conditioned media (p=0.3). 
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Figure 42.  Effect of Notch inhibition on levels of phosphorylated ERK in response to 
SMC derived soluble factors.  ECs were plated on Petri dishes and stimulated with SMC-
conditioned media either in the presence or absence of DAPT. 
  Effects of Notch on Angiogenesis in Response to SMC-Derived Factors 
In order to test the effects of Notch inhibition on angiogenesis in a 3-D 
environment, preliminary studies were done testing the uptake of eosin, a molecule of 
similar molecular weight to DAPT, to demonstrate penetration of drug into the 
hydrogel.(Figure 43)  Positive control groups demonstrated that the fluorescence of eosin 
persisted throughout the 48 hour time course when cultured in media.  In experimental 
groups, uptake of eosin into hydrogels from the media approached a steady state level by 
48 hours, with 55% of eosin uptake occurring within the first 4 hours of incubation, and 
89% by 24 hours.  The final steady state values did not significantly differ from the 
predicted amounts based on the volume occupied by the hydrogel and media.   
  
 
102 
 
Fi
gu
re
 
43
.
 
 
Eo
sin
 
u
pt
ak
e 
in
 
fib
rin
 
hy
dr
o
ge
ls.
 
 
Fi
br
in
 
hy
dr
o
ge
ls 
w
er
e 
cu
ltu
re
d 
in
 
m
ed
ia
 
co
n
ta
in
in
g 
th
e 
flu
o
ro
ph
o
re
 
eo
sin
.
 
 
 
Fl
u
o
re
sc
en
ce
 
in
 
th
e 
ge
l a
n
d 
th
e 
m
ed
ia
 
w
as
 
m
ea
su
re
d.
 
 
*
 
<
 
.
05
.
 
 
103 
 
 
The effect of EC Notch inhibition with DAPT on the angiogenic response to 
SMC-conditioned media was determined.  After 72 hours, the average length of EC 
sprouts in groups that were cultured in the presence of SMC-conditioned media was 
289% of controls (289.1 +/- 32.0 vs. 100.0 +/- 43.5%; p= .003).  The length of EC 
sprouts in groups treated with DAPT cultured in the presence of SMC-conditioned media 
was significantly less than ECs untreated with DAPT and cultured in the presence of 
SMC-conditioned media (172.6 +/- 20.4% vs. 289.1 +/- 32.0% of controls for DAPT 
treated and untreated ECs, respectively; p=.01) (Figure 44).  The length of EC sprouts in 
groups treated with DAPT cultured in the presence of SMC-conditioned media did not 
significantly differ from DAPT-untreated controls cultured in the presence of 
unconditioned media (172 +/- 20.4% vs. 100 +/- 43.5%; p = .15). 
 
Figure 44.  Effect of Notch inhibition on angiogenesis in response to SMC derived 
soluble factors.  ECs were aggregated and embedded within fibrin hydrogels.  They were 
cultured in SMC-conditioned media either in the presence of absence of DAPT. 
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Discussion 
 Notch is an evolutionarily conserved cell signaling pathway which, among a 
diverse set of functions, plays a critical role in angiogenesis regulation.  The specific 
effects of Notch on angiogenesis, and the specific factors which modulate those effects, 
are still somewhat unclear.  Further, the effects of Notch signaling in ECs in response to 
pericyte-mediated effects on angiogenesis are largely unknown.  In the studies presented 
in this Aim, we demonstrate that Notch inhibition with DAPT, a known inhibitor of 
gamma-secretase, inhibits the decrease in endothelial cell phosphorylated Akt seen after 
treatment with SMC-conditioned media.  Thus, we show that active Notch signaling in 
ECs is required for the reduction of active Akt in response to soluble factors released by 
SMCs.  Whether the effects of SMC conditioned media on levels of phosphorylated Akt 
are directly attributable to the modulation of kinase phosphorylation or phosphatase 
dephosphorylation of Akt, or both, is not known.  Further we show that while SMC-
conditioned media promotes the sprouting of endothelial cells in an in vitro angiogenesis 
assay, Notch inhibition attenuates this response, suggesting that active Notch in 
endothelial cells is required for the increased EC sprouting in response to SMC-derived 
soluble factors. 
  Notch has become an increasingly attractive target for strategies that aim to 
modulate angiogenesis.  The bulk of this research is directed toward the treatment of 
oncologic disease, with the purpose of modulating Notch-mediated tumor angiogenesis 
and invasiveness.  Inhibitors of gamma secretase, a proteolytic enzyme required for 
Notch activation, have been studied for this purpose.  The mechanism of Notch inhibition 
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by DAPT is attributable to the inhibition of the second of two proteolytic cleavages of the 
Notch receptor after binding to Notch ligand.  DAPT inhibits this intramembrane 
cleavage step catalyzed by the integral membrane multi-subunit gamma-secretase 
complex.  This prevents the release of NICD (Notch intracellular domain), which is the 
intracellular domain that translocates to the nucleus and leads to gene transcription.209  
While commonly used as an inhibitor of this key proteolytic step, DAPT may also affect 
other pathways.  Substrates of gamma-secretase which have been identified to date 
include the β-amyloid precursor protein, Erb-B4, E- and N-cadherins, CD44, the low 
density lipoprotein receptor, Nectin-1, and the Notch ligands Delta and Jagged.210  In 
addition to inhibition of the Notch pathway, DAPT has been evaluated has a potential 
pharmacologic option for the treatment of Alzheimer’s disease, but how DAPT 
selectively modulates the cleavage of each of the above listed substrates and the 
subsequent intracellular events is not fully clear, is likely quite complex, and is beyond 
the scope of this discussion.  Certainly non-specific proteolytic cleavages may affect EC 
surface proteolytic enzymes which may affect angiogenesis, although this is speculation.  
Proteolytic events related to Notch ligands may affect endothelial cell signaling responses 
mediate by these ligands.  To the knowledge of the author, there is no clear connection 
between these above described pathways and Akt or Erk activity in ECs or angiogenesis 
in response to SMCs.  However, while DAPT is commonly used as a gamma-secretase 
inhibitor for the purposes of Notch inhibition, possible non-Notch related responses in 
ECs must lead one to use caution in interpreting the results of the experiments in these 
Aims. 
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 The action of various gamma secretase inhibitors on angiogenesis in vitro and in 
vivo are still unclear, with both increased and decreased angiogenesis being demonstrated 
in response to gamma secretase inhibition.  Several studies, however, have suggested that 
the resulting microvasculatures tend to demonstrate abnormal function and structure.   
Kalen et. al., for example, demonstrated that while Notch inhibition led to increased 
vascular density of tumors, vasculatures in animal models treated with gamma secretase 
inhibitors form abnormal blood vessels characterized by vessel occlusion, disrupted 
blood flow, and increased vascular leakage.211   
 In our studies, we show the apparent pro-angiogenic function of active Notch 
signaling, as the inhibition of Notch with DAPT inhibited the sprouting response of ECs 
to SMC-conditioned media.   This is in apparent contrast to other studies that demonstrate 
the function of Notch in downregulating pro-angiogenic behavior. 200-204  Based on 
Western blot studies, the Dll-4 is the dominant Notch ligand present on ECs, while 
Jagged-1 was undetectable.  Dll-4 is thought to a negative regulator of angiogenesis,212 
which further complicates the response of ECs to SMC-conditioned media, as one would 
expect that inhibiting Notch signaling in ECs would primarily inhibit Dll-4 mediated 
Notch signaling in ECs, which should theoretically lead to increased angiogenesis in 
Notch inhibited cells.  These studies suggest that the identity of the Notch ligand cannot 
be the sole factor for the pro- or anti-angiogenic responses, that these responses are at 
least in part modulated by other factors.  We suggest that the apparent contradiction of 
our results to results of studies which investigate the role of Notch signaling in ECs 
primarily in the context of VEGF stimulation, is likely due to the identity and 
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combination of cytokines and growth factors released by SMCs in our model.   Future 
studies are required to examine these issues.  However, the demonstration that ERK 
phosphorylation occurs in a Notch independent manner when ECs are stimulated with 
FGF-2 in combination with VEGF is consistent with this hypothesis, as ERK 
phosphorylation in response to VEGF alone has been shown by others to be Notch 
dependent. 202  In addition, the concentration of DAPT (25µM) utilized in these studies 
have effectively inhibited endothelial cell proliferation and migration in response to 
VEGF,213 while dose response curves have demonstrated potent inhibition of Notch 
signaling at concentrations as low as 1µM.214 Dose-specific effects demonstrated in these 
and other studies may account for the potential discrepancy of the results seen in our 
experiments with other studies. 
 It would be interesting if the demonstrated increased Akt phosphorylation, 
thought to be a survival signal, in endothelial cells treated with DAPT reflected Notch-
associated conversion to a less stable EC phenotype responsible for a more dynamic 
developing microvasculature.  The Ang1/Tie-2 signaling system, thought to be a key 
signal for microvascular quiescence and stability, is an upstream regulator of Akt 
phosphorylation.196  The demonstration that Ang-1 potentiates vascular quiescence by up-
regulating Dll4 through Akt-mediated activation of β-catenin suggests a link among Ang-
1/Tie-2 , Akt, and Notch signaling.215  Ang-2, a competitive antagonist of Ang-1 that 
prevents Tie-2 receptor phosphorylation and signaling, is involved in the disruption of the 
endothelial monolayer, and promotes EC survival, vessel sprouting and angiogenesis.216-
219
  The potential secretion of Ang-2 by SMCs could hypothetically disrupt basal Ang-1 
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signaling and lead to the decrease in basal levels of phosphorylated Akt in ECs.  As 
previously noted, the requirement for active EC Notch signaling in the demonstrated 
SMC-induced decrease in phospho-Akt suggests that EC Notch is an upstream regulator 
of Akt dephosphorylation.  Thus, a hypothetical pathway is that SMCs release Ang-2 or 
induce the release of Ang-2 from EC Weibel-Palade bodies by secreting other factors 
such as VEGF and FGFs.  This release of Ang-2 then inhibits Tie-2-mediated Akt 
phosphorylation in a Notch dependent manner, and converts ECs from a quiescent 
phenotype to a synthetic phenotype leading to the pro-angiogenic response to SMC-
conditioned media.   The demonstration that Notch signaling is required for the induced 
expression and activation of specific proteases in response to VEGF supports the 
hypothesis that Notch can regulate pathways which lead to the “synthetic” behavior of 
activated endothelial cells.220 This is consistent with the observation that Notch is 
required for the pro-angiogenic response to SMC-conditioned media.  The specific role of 
Dll-4, the expression of it or other Notch ligands and receptors, and specific Notch 
receptor and ligand combinations on mediating this pathway is also unknown. 
 It would be of interest to study the effects of delivery of a constitutively active 
Akt to determine if the decrease in active Akt was a direct upstream regulator in the 
induction of angiogenesis in response to SMC-conditioned media. In this case, one would 
not expect ECs cultured in SMC-conditioned media to demonstrate any increase in 
angiogenesis compared with controls.  The role of Akt activity as a mediator of Notch 
dependent angiogenic induction in response to SMC-conditioned media could also be 
tested in cells expressing constitutively active Akt.  The use of selective Akt inhibitors 
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such as LY compound could be used to corroborate these experiments.  The reduction of 
active Akt at basal levels would be expected to increase angiogenesis if inactive Akt is 
associated with the induction of angiogenesis.   Future studies using Notch-
overexpressing ECs cultured in the presence and absence of SMC-conditioned would be 
required to determine whether the Notch mediated response to SMC-conditioned leads to 
functional or abnormal EC microvasculatures.  Further, the interaction between Notch 
receptor and ligand activity or expression in response to SMC-conditioned media has not 
been quantified in these studies and would be a subject of future investigations.   
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CHAPTER SEVEN 
SUMMARY OF RESULTS AND CONCLUSIONS 
The following are the major findings of the above discussed studies (Figure 45). 
 
Figure 45.  Summary of results.  Aggregated ECs in fibrin form sprouts containing 
lumens which are surrounded by SMCs, resembling native capillaries histologically.  
SMCs promote the formation and persistence of the engineered 3-D capillary structures, 
in part by the release of soluble factors into the extracellular environment.  These SMC-
released products have the effect of increasing phosphorylated ERK 1/2 and 
unphosphorylated Akt in ECs.  The increase in unphosphorylated Akt in ECs in response 
to SMC-released factors is EC Notch dependent.     
Aim 1 
 ECs co-cultured with SMCs form angiogenic sprouts in 3-D fibrin hydrogels.  
Transmission electron microscopy and fluorescence microscopy demonstrate lumen 
formation and SMC/EC colocalization in capillaries. 
VEGF delivered in combination with FGF-2 induces angiogenic network 
formation in fibrin hydrogels, and SMCs do not inhibit the angiogenic response of ECs to 
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these growth factors.  After the withdrawal of VEGF and FGF-2, SMCs promote both the 
formation and persistence of fibrin-based microvasculatures.  In the absence of SMCs, 
growth factor withdrawal led to microvascular regression.  
In the absence of exogenous angiogenic factors, SMCs promote the formation and 
persistence of angiogenic networks in fibrin hydrogels.  The presence of direct contact 
between the two cell types does not inhibit this effect.  In fact, ECs and SMCs co-invade 
into the ECM in a direct contact angiogenesis model, and the inhibition of SMC 
proliferation/matrix invasion alone inhibits both EC and SMC invasion. 
Aim 2 
 Sprouts from co-cultured aggregates demonstrate directed invasion towards one 
another.  Media conditioned by SMCs is mitogenic, chemotactic, and angiogenic for ECs 
and induces ERK phosphorylation in ECs.  SMC-conditioned media suppresses serum 
induced basal Akt phosphorylation in ECs. 
Aim 3 
 VEGF in combination with FGF-2 induces both ERK and Akt phosphorylation in 
ECs after 20 minutes of stimulation.  This returns to unstimulated levels after 48 hours of 
continuous growth factor stimulation, and ERK and Akt protein levels are not altered by 
48 hours of stimulation with VEGF + FGF-2. 
 Inhibition of EC Notch signaling by DAPT increases Akt phosphorylation in 
response to 20 minutes of VEGF + FGF-2 stimulation.  This returns to unstimulated 
levels after 48 hours of continuous growth factor and DAPT treatment.  Notch inhibition 
with DAPT does not alter Akt protein levels.  Neither ERK phosphorylation nor protein 
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levels after 20 minutes and 48 hours of stimulation, respectively, with VEGF + FGF-2 is 
affected by Notch inhibition with DAPT. 
 Dll-4 is the predominant Notch ligand in ECs; Notch 1 is the predominant Notch 
receptor in ECs.  Stimulation with VEGF + FGF-2 for 48 hours did not alter the identity 
of Notch receptors or ligands in ECs or SMCs. 
 Inhibiting Notch signaling with DAPT reverses the dephosphorylation of Akt by 
SMC-conditioned media.  Notch inhibition does not affect the phosphorylation of ERK in 
response to SMC-conditioned media.  Inhibiting Notch signaling with DAPT reverses the 
induction of angiogenesis by SMC-conditioned media. 
Overall Summary of Major Findings 
 An ex vivo SMC/EC co-culture strategy is capable of engineering microvascular 
networks that resemble native capillaries in fibrin hydrogels.  SMCs do not attenuate the 
early pro-angiogenic effects of exogenously delivered VEGF + FGF-2 on fibrin-based 
microvascular networks.  SMCs promote the early formation and later persistence of 
fibrin-based microvascular networks in part by release of soluble factors and can do so in 
the absence of any exogenous growth factor delivery. 
 VEGF + FGF-2 induces the phosphorylation of ERK and Akt in endothelial cells.  
Active endothelial cell Notch signaling suppresses the phosphorylation of Akt in 
response to VEGF + FGF-2.  The abundance of Dll-4 on ECs suggests that it may be the 
ligand through which these effects occur.  The phosphorylation of ERK in response to 
VEGF + FGF-2 is independent of Notch signaling. 
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 SMC-released factors promote phosphorylation of ERK and dephosphorylation of 
Akt in ECs, and promote the proliferation, migration, and early sprouting of ECs.  Active 
endothelial cell Notch signaling is necessary for the dephosphorylation of Akt in response 
to SMC-released factors.  Active endothelial cell Notch signaling is necessary for the 
induction of angiogenesis in response to SMC-released factors.  The abundance of Dll-4 
on ECs suggests that it may be the ligand through which these effects occur. 
 
 
  
114 
CHAPTER EIGHT 
CONCLUDING REMARKS 
 Overall, we have demonstrated a method for engineering microvasculatures in 
fibrin, a hydrogel commonly used in tissue engineering.  We hypothesize that the 
prevascularization of the walls of tissue engineered blood vessels will provide benefits on 
medial cell viability, reduce intimal hyperplasia, promote graft endothelialization, and 
improve the mechanical biocompatibility of tissue engineered blood vessels.  We believe 
that the delineation of these potential effects would be important studies for the 
advancement of the creation of a clinically efficacious tissue engineered blood vessel.  
Additionally, we have attempted to delineate some of the basic cellular and molecular 
processes that modulate the development of these microvasculatures in a 3-D 
extracellular environment.  The Notch pathway is a known mediator of angiogenesis and 
has implications both in oncologic therapies as well as for the regulation of angiogenesis 
in tissue engineering. 213,221  These studies may offer insights into potential protein and 
genetic targets for the manipulation of angiogenesis, which may be beneficial in both 
selectively promoting and inhibiting angiogenesis.  Further studies to more clearly 
delineate how these processes mediate angiogenic activity during specific stages of 
microvascular development would provide for more precise therapeutic interventions.  
In addition, it is important to recognize some of the major limitations of these 
studies.  The inherent inaccuracies of in vitro models of basic biologic processes in 
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relation to the in vivo environment may be a contributing factor to the results of these 
studies.  These studies utilize several cell types (both ECs and SMCs), signaling 
pathways, delivered proteins, culture media, and extracellular matrix proteins.  Each of 
these factors can affect the results of these studies, with specific cellular and molecular 
responses contingent on the doses, reagents, concentrations, etc. used in these 
experiments.   Also, as alluded to in previous discussions, the processes investigated, 
specifically in the second and third Aims, likely represent events which are occurring 
early in the process of angiogenesis.   The SMC-mediated induction of angiogenesis, the 
activation and deactivation of ERK 1/2 and Akt, respectively, and the regulation of these 
events by EC Notch signaling are likely occurring within the first 72 hours of 
angiogenesis.  This is not to say, however, that the later events occurring after pericyte 
incorporation or microvascular stabilization are occurring independent of early events.  It 
is highly likely that these early processes, by the secretion of growth factors and 
cytokines, the deposition of extracellular matrix, or the regulation of signaling pathways 
affect cellular behavior via negative (or positive) feedback loops which may serve to 
counteract and “turn off” the early angiogenic events as the angiogenic process 
progresses.  This discussion is mostly speculative at this point, however, and further 
investigations into how early events in angiogenesis affect the later events would be 
interesting to perform. 
 A final, and especially important consideration related to the above-described 
studies is the choice of fibrin as the extracellular matrix.   The ECM is a highly important 
modulator of angiogenesis during oncogenesis, wound healing, and development.  For 
example, the differentiation of ECs grown as a monolayer in vitro into branching tubule 
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structures has been shown to require the coverage of cells with collagen and the 
establishment of appropriate cell-matrix interactions.222  Angiostatic molecules like 
thrombospondin-1 (TSP-1) and interferon-inducible protein-10 have been shown to be 
less effective in inhibiting VEGF-induced EC proliferation when cultured on type-I 
collagen, an observation that has intuitive implications in the clinical use of pro- or anti-
angiogenesis drugs.223  Laminin, a non-collagen hetero-trimeric (3 chains: α, β, and γ) 
glycoprotein found in basement membrane and granulation tissue, has been shown to 
increase EC-ECM attachment and migration in vitro,224 is produced throughout the length 
of EC sprouts and has been shown to limit proliferation and lumen size,225 and is 
associated with breast and brain cancer neovascularization and membrane invasion (i.e. 
laminin-8 and laminin-10).226,227  Fibronectin, often an injury response protein, is actively 
unfolded by ECs and serves as an ECM scaffold for cellular matrix deposition and 
neovascularization,228 while combinations of other proteins active in wound healing, like 
hyaluronic acid, type I collagen and fibrin, can have differential angiogenic effects 
compared to when they are present alone.229,230  
 While the composition of the ECM is clearly an important factor in the regulation 
of angiogenesis, the organizational structure of the ECM is also key.  Studies have 
demonstrated in numerous cell types that cell culture in 3-D environments vs. 2-D 
environments can significantly impact the expression of differentiation markers, diminish 
cell proliferation, and affect the expression of proteins like MMP-2.231,232  Physical 
characteristics such as fiber thickness, density, orientation, cross-linking, and pore size 
have all been shown to affect the number, length, and cross-sectional area of angiogenic 
sprouts.72,233,234  In vitro, ECs have been shown to demonstrate decreased cell migration 
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and invasion with increased capillary morphogenesis in fibrin as the rigidity is decreased 
by altering pH, NaCl concentration, and thrombin content. 235-237  In chick chorioallantoic 
membrane (CAM) angiogenesis assays, significantly more sprout invasion is associated 
with a reduction in fibrin substrate concentration, and the physical characteristics of the 
ECM were found to be as important as the presence or absence of growth factors such as 
FGF and VEGF.229   
 In tissue engineering, fibrin has been utilized as a scaffold for TEBVs with its 
own distinct set of advantages and disadvantages.  In comparison to collagen hydrogels, 
for example, fibrin has been found to promote increased native collagen production by 
entrapped fibroblasts and SMCs, suggesting its ability to support the matrix remodeling 
processes involved in host tissue incorporation after implantation.238  The presence of 
deposited elastin in fibrin hydrogels as compared to collagen hydrogels also suggests 
potentially beneficial effects on cell mediated matrix remodeling processes affecting 
construct biomechanics.239,240  Implantation of fibrin-based TEBVs into lamb external 
jugular veins demonstrated endogenous collagen and elastin deposition by SMCs in the 
arterial media which orientated circumferentially in a direction which was perpendicular 
to circulatory blood flow.241  Interestingly, these TEBVs gained mechanical strength and 
vasoactivity which were comparable to that of native blood vessels after 15 weeks in 
vivo.  Fibrin-coated vascular prostheses have been evaluated in animal models for 
coronary artery bypass.242  While early results were encouraging with patency up to 12-2 
days, thrombus formation and platelet deposition as well as degradation of the hydrogel 
after the first two weeks limited the efficacy of these prostheses. As in collagen-based 
constructs, the mechanical strength of fibrin-based TEBVs in general remains a 
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significant limitation and often requires the use of synthetic polymers such as 
polyvinylidene fluoride mesh to improve the mechanical stability of fibrin-based 
TEBVs.243  However, given the benefits of fibrin as a scaffold for tissue engineered 
constructs, or at least as a component of the scaffold, in addition to its utility as a drug 
and cell delivery system, we have adopted a fibrin based in vitro angiogenesis model.  
Investigating the specific cell, molecular, and fibrin interactions in mediating the effects 
seen in the results of these Aims would be an interesting and worthwhile pursuit in the 
future.  
  
 [119] 
APPENDIX A: 
LIST OF MEDIAS USED IN EXPERIMENTS
[120] 
 
 
EC Complete Media 
  M199, 10% FBS, PCN/Strep (100 U/mL), Amphotericin (.25 µg/mL), FGF-1 (5 
ng/mL), heparan sulfate (5U/mL) 
SMC Growth Media  
 DMEM, 10% FBS , PCN/Strep (100 U/mL), Gentamicin (.05 µg/mL), 
Amphotericin (.25 µg/mL), non-essential amino acids, MEN, sodium pyruvate 
Angiogenesis Assay Media 
 M199, 10% FBS, PCN/Strep (100 U/mL), Amphotericin (.25 µg/mL), aprotinin 
(100 KIU/mL), heparan sulfate (5U/mL)  
Migration Assay Media 
 M199, 1% FBS, PCN/Strep (100 U/mL), Amphotericin (.25 µg/mL), aprotinin 
(100 KIU/mL), heparan sulfate (5U/mL)   
Proliferation Quiescence Media 
 DMEM-F12, PCN/Strep (100 U/mL), L-ascorbic acid, insulin, transferrin 
Notch Signaling Assay Stimulation Media 
 M199, 2.5% FBS, PCN/Strep (100 U/mL), Amphotericin (.25 µg/mL), aprotinin 
(100 KIU/mL), heparan sulfate (5U/mL), +/- VEGF + FGF-2 (10 ng/mL for each growth 
factor), +/- DAPT (25µM) or DMSO 
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